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ABSTRACT
ADDRESSING THE PROBLEM OF STERILE DRUG INJECTING SUPPLY
ACQUISITION FOR PEOPLE WHO INJECT DRUGS
Barbra A. Cave
December 13, 2019
This dissertation contains five chapters, including three manuscripts, covering
harm reduction and some of the challenges people who inject drugs (PWID) face in their
effort to reduce the risk of injection drug-related harms through sterile injecting supply
acquisition and use. Chapter One discusses some background related to PWID and
provides an overview of the issues addressed in this dissertation. Chapter Two includes a
literature review covering the harm reduction concept, important aspects of syringe
exchange programs as a harm reduction tool, and the social determinants of health model
as a potential tool for future research. Chapter Three is a two-phase study that examines
the problem of syringe and drug injecting equipment sharing and reuse among PWID
participating in a syringe exchange program. This study explores the scope of the
problem, then uncovers reasons contributing to syringe sharing and reuse behavior.
Findings are applied to the social determinants of health model, with results
demonstrating a number of social determinants that influence PWID behavior. In Chapter
Four the author highlights approaches to sterile drug injecting supply acquisition used by
PWID and presents policy alternatives. Finally, there is a discussion of a case study and
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description of how nurses can ethically support harm reduction strategies for PWID.
Chapter Five contains a summary of findings and recommendations for future work.
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CHAPTER I
INTRODUCTION & OVERVIEW
Injection drug use is an increasing problem both worldwide and in the United States.
From 2004 to 2014, the United States saw an 89% increase in the rate of opioid injection
(Zibbell et al., 2018). Rates of any drug injection increased 76% over the same time
period (Zibbell et al., 2018). People who inject drugs (PWID) are at risk for a multitude
of negative consequences. Social consequences may include loss of employment, family
disruptions, and loss of housing. Legal consequences may include arrest and prosecution,
and confiscation of drugs and paraphernalia. Perhaps the most severe consequences are
related to health. PWID experience high rates of skin and soft tissue infections, blood
stream infections leading to endocarditis and/or sepsis, and acquisition of infectious
disease such as hepatitis C virus (HCV), hepatitis B virus (HBV), and human
immunodeficiency virus (HIV) (CDC, 2019; Des Jarlais, 2017; Havens et al., 2013;
Zibbell et al., 2018). These negative health consequences lead to significant morbidity
and mortality among PWID, and are costly to the healthcare system.
Harm reduction is a set of tools and strategies aimed at reducing the harms caused
by drug use, and careful attention is paid to PWID. Harm reduction can take place in any
setting—from healthcare provider offices, addiction care centers, syringe exchange
programs (SEPs), and more (Hawk et al, 2017). In the United States, one example of
increased efforts towards harm reduction has taken place through increasing numbers of
SEPs. Kentucky has the most SEPs of any states, and has increased the number of them
1

from one in 2015, to 69 in 2019 (KDPH, 2019). As the number of programs grow not
only in Kentucky but nationwide, it is important to understand how PWID interact with
and participate in such programs. Program evaluation and data tracking are SEP best
practices, and they may provide clues to models that are working well as well as identify
potential issues. In 2017, a SEP in Kentucky surveyed its participants as part of this
process and found reports of continued syringe and drug injecting equipment sharing and
reuse among their participants (M. LaRocco and W. Crabtree, personal communication,
January 16, 2017). Sharing of drug injecting equipment undermines some of the
important health benefits of SEPs.
In an effort to understand the frequency of syringe and drug injection equipment
misuse among SEP participants, a literature search was conducted. Some studies included
information on syringe sharing for people reporting SEP participation. Luo et al. (2014)
found PWID in China who had ever participated in SEP had lower odds of having HIV
(n= 3,494), but they also found people who had attended SEP reported higher rates of
syringe sharing than non-SEP attendees (OR=1.67, 95% CI=1.19–2.32, p=0.0031).
Beletsky et al., (2014) found 51.4% of people with inconsistent use of SEP reported
receptive syringe reuse (n=514, (OR=1.15, 95% CI=0.72-1.81, p<0.01). Bluthenthal, et
al. (2000) found PWID who had initiated and continued to use SEP reported cessation in
syringe sharing behavior (204 of 340 PWID). Hartgers, van Ameijden, van den Hoek,
and Coutinho (1992) reported 24% of routine SEP participants engaged in receptive
syringe reuse (18 of 75 PWID). Most of the literature was limited to receptive syringe
reuse. This author wished to investigate the prevalence of any drug injecting equipment
misuse (sharing used equipment with others, personally reusing previously used
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equipment, using equipment previously used by another person, and sharing of sterile
supplies among PWID engaged SEP), and uncover factors and influences associated with
such behavior.
To prepare for such a study, the author reviewed available literature to better
understand the perspectives people who use drugs (PWUD) hold of harm reduction. Next,
the author examined harm reduction best practice guidelines and thoroughly explored
harm reduction elements, concepts, and principles. As SEPs are a common platform for
harm reduction, she detailed SEP models and compared them to the best practice
recommendations. She then highlighted the models used within Kentucky, and explored
how the social determinants of health (SDOH) model could influence PWID participation
in a SEP.
The SDOH model was originally described by Marmot and Wilkinson in 2006. The
model appreciates health influences are not merely a result of race, ethnicity, genetics,
gender or individual behavior, and that actions can be taken to improve the health of
populations (Marmot & Wilkinson, 2006). The World Health Organization adapted and
refined the model, and identified key concepts such as economic stability, education,
health and healthcare, neighborhood environments, and social contexts that include
employment conditions, social inclusion, public health programs, women and gender
equity, early childhood development, globalization, health systems, and measurement and
evidence, and urbanization (WHO, 2019).
The SDOH model has been used by nurses caring for people who use drugs
(PWUD) in an opioid substitution program (Gadbois, Chin, & Dalphonse, 2016). The
authors recognized limited access to social determinants were substantial barriers to
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improving the health of people who use drugs in an addiction care program. The authors
used the SDOH model as a tool for developing a quality improvement program that
involved nurses and multidisciplinary staff at an urban hospital. Outcomes demonstrated
improved assessment of SDOH and care coordination for people in the program
(Gadbois, Chin, & Dalphonse, 2016).
The author used the SDOH as a theoretical framework to help design and analyze the
study. Having prevalence estimates of syringe misuse behavior helped uncover the scope
of the problem, while interviews helped explain what was happening when misuse
occurred. Subjects were quantitatively surveyed and/or qualitatively interviewed using a
focused ethnographic approach. The study was approved by the University Institutional
Review Board, and a certificate of confidentiality was obtained from the National
Institutes of Health to help protect this vulnerable population. Subjects were recruited
using convenience sampling from an urban SEP in a southern state. Four themes
uncovered behavioral/situational factors associated with drug injection equipment
misuse. Each theme was explored using the SDOH model and examples of determinants
were identified in the data.
After uncovering the scope of drug injecting equipment sharing and reuse among
the sample and learning which SDOH impact program participation in terms of visit
frequency and supply limitations, the author sought to explore alternative methods of
drug injecting supply acquisition, and describe how support for harm reduction is an
important ethical undertaking for nurses caring for PWID. Alternative methods included
secondary exchange (receiving sterile supplies from someone who attended a SEP),
pharmacy syringe sales, injection supply vending machines, and trade or drug dealer sales
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(where the dealer supplies sterile equipment in trade or as an outright sale). Policy
alternatives aimed at increasing access to sterile drug injecting equipment were explored.
Alternatives included supply vending machines, SEPs on mobile units, formal support for
secondary exchange practices, elimination of restrictive syringe distribution models
within SEPs, and increased support for supply sales within pharmacies. A case study
example of policy alternatives in action described how the situation in Kentucky’s SEPs
could improve through elimination of supply distribution limits and bolstering pharmacy
syringe sales and increased harm reduction support from pharmacists. Informing PWID
on ways to access sterile injecting supplies is an ethical nursing activity, and the
principles of harm reduction are in line with the American Nursing Association (ANA)
Code of Ethics (2015). Harm reduction is supported by the ANA, and resources are
available to assist them in incorporating principles into patient care (ANA, 2018).
The role harm reduction plays in mitigating the negative health consequences for
PWID is especially clear in SEPs. Uncovering and exploring the SDOH’s impact on the
ability of PWID to fully participate in harm reduction is important. The work of this
author described some of the problems faced by PWID in accessing sterile injecting
supplies, and provided evidence on the estimation of syringe and injecting equipment
misuse among PWID already engaged in harm reduction services. Future work should
identify effective strategies in overcoming SDOH barriers and finding ways to achieve
positive change through policy alternatives.
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CHAPTER II
EXPLORING HARM REDUCTION, SYRINGE EXCHANGE PROGRAMS, AND
SOCIAL DETERMINANTS OF HEALTH: A LITERATURE REVIEW
Overview
Introduction: Kentucky is leading the nation in new cases of hepatitis C virus (HCV)
infection and is at substantial risk for a widespread human immunodeficiency virus (HIV)
outbreak. These risks are directly tied to the ongoing opioid epidemic, with the
Appalachian region of the United States demonstrating the highest rates of injection drug
use. Syringe exchange programs (SEP) are a form of harm reduction aimed at reducing
drug-related harms, including the spread of infectious disease and the development of
skin infections and endocarditis. Syringe exchange programs are widely available across
Kentucky, but people who inject drugs (PWID) may be underutilizing their services. The
social determinants of health (SDOH) model may help explain PWID behavior in the
context of SEP participation and drug injection equipment misuse. The purpose of this
review is to describe harm reduction, syringe exchange programs, and SDOH model to
guide future research aimed at uncovering what influences PWID decisions regarding
drug injection equipment misuse. Methods: A systematic review of literature using
PubMed (MEDLINE) and CINAHL were used to briefly synthesize what is known about
PWID perceptions of harm reduction and best practices in SEP. Results: PWID have
positive perceptions of harm reduction but may remain at risk for acquiring HCV and/or
HIV infection through inconsistent use of harm reduction approaches and full utilization
6

of SEP services. SEP services in the region are not following best practices in limiting
distribution quantities of supplies. The SDOH model may help explain why PWID are
unable or unwilling to avoid high-risk injection practices, such as sharing used injecting
equipment when faced with supply restrictions. Future research should examine the
degree of injecting equipment misuse among SEP participants, and describe what
influences PWID’s decisions regarding exclusive use of sterile equipment from SEP
using SDOH as a framework.
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Background
Hepatitis C virus (HCV) is spread through blood-to-blood transmission and may
lead to severe morbidity from chronic liver disease, cirrhosis, liver failure, and cancer; in
some cases, it leads to death or organ transplantation. Hepatitis C virus infection may
lead to complications or worsening diseases outside of the liver, including lymphoma,
membranoproliferative glomerulonephritis, lichen planus, porphyria cutanea tarda, and
insulin resistance (Ansari, Henderson, Stott, & Parr, 2017; Barsoum, William, & Khalil,
2017; Desbois & Cacoub, 2017; El-Maadawy et al., 2016; Garcovich, Garcovich,
Capizzi, Gasbarrini, & Zocco, 2015). Hepatitis C virus infection is the most common
blood borne disease in the world (Shepard, Finelli, & Alter, 2005). There are an estimated
170 million people worldwide infected with the virus, representing 2-3% of the world’s
population (Averhoff, Glass, & Holtzman, 2012). More than 350,000 people die each
year due to complications resulting from HCV infection (Averhoff et al., 2012).
In the United States, an estimated 5.2 million people are infected (Chak, Talal,
Sherman, Schiff, & Saab, 2011). Similar to global distribution of HCV, prevalence rates
vary state-to-state, and mirror the ongoing issues related to injection drug use. For
example, the U.S. Appalachian region, which includes Tennessee, Ohio, Virginia, and
Kentucky, opiate prescribing was exceptionally high. This same region is now faced with
an HCV epidemic that is perpetuated through the increased use of injected heroin in
response to changes in opiate prescribing laws (Christian, Hopenhayn, Christian,
McIntosh, & Koch, 2010; Stephens & Havens, 2013). The primary means of acquiring
HCV is through injection drug use, but exposure is possible through accidental needle
sticks, blood transfusions performed before 1992, having unregulated tattoos, men who
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have sex with men, transmission from mother-to-baby during pregnancy, and through
healthcare-related procedures (Abdelwahab & Ahmed Said, 2016; Koneru et al., 2016).
Human immunodeficiency virus (HIV) is transmitted via blood-to-blood, in utero,
and sexual contact. Infection with HIV may lead to the development of other diseases
through opportunistic infection (HCV, Herpes zoster, Cytomegalovirus, Shigella,
Syphilis, M. tuberculosis, Leprosy, Pneumocystis jiroveci, Scabies, Trichomonas, etc.),
malignancies (Kaposi sarcoma, Hodgkin’s lymphoma, anal carcinoma, etc.), and chronic
disease (cardiomyopathy, cerebral vasculitis, sarcoidosis, Guillain-Barre syndrome,
Grave’s thyrotoxicosis, etc.) (Lucas & Nelson, 2015).
An estimated 35 million people worldwide are living with HIV; 2.3 million are
newly infected each year and 1.6 million die annually (Lucas & Nelson, 2015). In the
United States, approximately 1.1 million people are living with the virus (CDC, 2019).
The majority of new HIV cases are due to sexual transmission, but injection drug use
may lead to HIV infection (CDC, 2019; Des Jarlais, 2017). In 2016, an estimated 9% of
new HIV cases were linked to injection drug use (Avert, 2019). Similar to HCV, the
prevalence of HIV in the United States varies by region. The Southern states made up
52% of new HIV cases in 2017, even though they make up less than 30% of the United
States Population (CDC, 2019).
Significance
In general, HCV is more transmissible than HIV, especially among people who
inject drugs (PWID) (Havens et al., 2013). Syringe exchange programs (SEP) are one of
many harm reduction tools used to help stop the spread of infectious diseases like HCV
and HIV. In areas without SEP services, PWID are understandably vulnerable to
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acquiring one or both infections because sterile injecting supplies are difficult to obtain,
and injection practices are risky due to lack of harm reduction education (Havens et al.,
2013). In Kentucky, SEP services began in 2015 in Louisville in an effort to combat the
growing opioid injection and HCV epidemics. In 2016, the Louisville Metro Department
of Public Health and Wellness (LMDPHW) SEP began receiving reports from clients that
they were sharing or reusing used drug injecting equipment despite their participation in
the program (M. LaRocco and W. Crabtree, personal communication, January 16, 2017).
What was unclear was how often this behavior occurred, and what the driving forces
behind it were. In review of literature, few studies reported on the prevalence of sharing
of used syringes among participants in a SEP (Luo et al., 2014; Beletsky et al., 2014;
Bluthenthal, 2000; Hartgers, van Ameijden, van den Hoek, & Coutinho, 1992), and no
literature was found examining prevalence personal syringe reuse or sharing of used
equipment with others among PWID already engaged in SEP services. The spread of
infectious disease is of high concern to all of Kentucky’s SEPs and those impacted by the
opioid epidemic, and it is well understood that syringe sharing and reuse are the primary
proponents of disease propagation within networks of PWID (Havens et al., 2013).
The purpose of this literature review is to describe the concept of harm reduction
and PWID perceptions of it in order to better understand if PWID have already identified
issues with harm reduction affecting the potential for syringe misuse; to describe SEP
best practices as a means of harm reduction; and to explore the utility of the social
determinants of health model as a framework to guide future research aimed at
uncovering what factors influence SEP-participating PWID’s decisions regarding drug
injection equipment misuse. Understanding the interplay between PWID perception, SEP
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best practices, and SDOH barriers may help future work with PWID to fully engage in
SEP services and limit syringe and drug injecting equipment misuse.
Harm Reduction
The concept of harm reduction evolved during the early 1990s in response to the
acquired immunodeficiency syndrome (AIDS) epidemic. The concept was defined in
1995 by Single, who states “harm reduction focuses on reducing the consequences of
drug use rather than eliminating drug use,” (Single, 1995, p. 288) and its applications
were described in the 1999 Canadian policy paper, Harm reduction, concepts and
practice: A policy paper (Riley, 1999). Harm reduction involves working with people
who use or abuse substances such as illicit drugs or alcohol, as well as policy makers, law
enforcement personnel, addiction specialists, and healthcare providers with a goal of
reducing the adverse physical and social harms associated with substance use (Des
Jarlais, Friedman, & Ward, 1993; Erickson, 1995; Gold, 2009).
The primary harm reduction tool is use of a non-judgmental approach to provide
straight-forward education, then allow the person using drugs to make their own
decisions (Gold, 2009; Single, 1995). Harm reduction is meant to provide behavioral
choices based on facts, which encourages substance users to exercise their autonomy to
potentially reduce social or physical detriment (Bartlett, Brown, Shattell, Wright, &
Lewallen, 2013). This approach is used for other stakeholders such as policy makers and
providers to reduce stigma and effect policies to enhance services to the targeted
population. In removing judgement and stigma, people who use drugs (PWUD) may be
more responsive to their health needs, are more likely to have access to, enter, and
receive appropriate addiction treatment, and may overcome difficult situations (Bartlett et
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al., 2013). It is important to understand that PWUD often feel stigmatized and
undeserving when interacting with healthcare providers; developing a sense of trust
through fidelity, competence, honesty, confidentiality, and strong connections with
healthcare providers and others who support PWUD increases their sense of trust
(Treloar, Rance, Yates, & Mao, 2016).
Eight principles for harm reduction practice have been described by the Harm
Reduction Coalition (2019). See Table 1. These principles serve as a flexible guide for
creating goals, taking action, and general considerations for PWUD. Harm reduction
strategies include syringe exchange programs, medication assisted therapy, supervised
injection sites, injection supply vending sites (also known as syringe vending sites), peer
exchange services, and more.
Table 1
Principles of Harm Reduction
Principle
1

Accept that drug use is part of reality, but work can be done to minimize its
effects. Drug use should not be ignored, nor condemned.

2

Understand that drug use encompasses a continuum of behaviors, from severe
abuse to complete abstinence, and that there are safer ways of using drugs.

3

Cessation of all drug use is not a criterion for measuring a successful policy or
intervention; consider individual or community quality of life as a criterion for
success.

4

Encourage a non-judgmental and non-coercive approach to providing services
(such as syringe exchange programs) in an effort to assist PWUD and their
communities to reduce drug-related harm.

5

Encourage PWUD to have a voice in the creation of programs and policies meant
to benefit them, rather than having programs and policies created for them
without input.

12

Table 1 (continued).
Principle
6

Recognize PWUD are their own primary actors in reducing harms of their own
use, and this encourages them to share information and support each other.

7

Many social inequalities affect PWUD’s vulnerability and capacity to effectively
manage drug-related harms.

8

Harm reduction does not attempt to minimize or ignore the real threats and
dangers associated with drug abuse, whether the drugs used are licit or illicit.

Note. (HRC, 2019).
As harm reduction principles are applied to new or expanding areas, knowing that
PWUD/PWID recognize the importance of the concept is important. Perceptions of harm
reduction among PWID have been reported in the literature. A systematic review using
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidance is shown in Figure 1. PubMed and CINAHL databases were searched without
time limits for articles published in English and in the United States using search terms
“harm reduction,” “people who inject drugs,” and “perception.” Titles and abstracts were
screened for relevance to the perception of harm reduction programs among PWID.
Table 2 displays details from the included studies. Three of the four studies are
qualitative and nature, and one was a cross-sectional survey.
Allen et al. (2019) qualitatively interviewed SEP participants in West Virginia and
determined those PWID found the SEP trustworthy, and had demonstrated value in
disease and overdose prevention (n=27). In rural Virginia, Baker et al. (2019)
quantitatively assessed community stigma of PWID by evaluating whether subjects felt
PWID were strong versus weak, deserving versus worthless, and if addiction was seen as
a disease versus a choice, where stigma is a negative perception held by others about a
population. Scores were compared to scores of community harm reduction support and
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compared to the stigma measures. The authors determined subjects who felt more stigma
towards PWID were less likely to support community harm reduction measures such as
SEP, while support for SEP was strongest among those who believe the program helps
reduce the spread of disease. A group of Chicago PWID participated in CarlbergRacich’s (2016) study which sought to determine if they were interested in receiving
harm reduction education as part of their HIV care, and how they perceived harm
reduction approaches. Subjects were supportive of harm reduction, and even expressed
enthusiasm; however, some reluctance to disclose their substance abuse status with their
provider was also present. In Philadelphia, Harris et al. (2018) qualitatively explored
PWID perceptions of supervised injection facilities, while also exploring where PWID
prefer to inject (i.e. at home, abandoned houses, or secluded public space), and what
factors lead to such a preference (n=42 PWID and 20 healthcare providers). The authors
found PWID were fully supportive of supervised injection facilities as a harm reduction
approach in mitigating the risks of drug injection in unsanitary conditions, and reported
that PWID also recognize the benefits to public health and safety with their use.
Results from all studies generally indicated that PWID in the United States
perceive harm reduction in a positive light, whether its principles are delivered in a
healthcare setting, supervised injection facility, or SEP. Holding a positive view of harm
reduction is important for PWID because it may influence their willingness to participate
SEPs. Participants in Allen et al (2019) anticipated a positive experience with harm
reduction in terms of safer injection counseling and supply provisions; Baker et al. (2016)
hope PWID participating in comprehensive harm reduction programs are able to
experience increased community support of harm reduction measures. Even when
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support for harm reduction exists, PWID remain vulnerable to pressures to engage in
syringe sharing and misuse (Allen et al. 2019). Nonetheless, PWID and crack cocaine
smokers remain vested in harm reduction programs and optimistic about their potential to
reduce drug-related harms, even if it is difficult to discuss ongoing drug use with
healthcare providers (Carlberg-Racich, 2016). .
Although there appears to be consensus among these studies, many questions
remain unanswered. For example, how do perceptions of harm reduction compare among
different PWID populations (rural versus urban, those with easy SEP access versus those
with difficulty accessing SEP) and how perception of harm reduction might change when
multiple types of programs are available. Another question to ask is why do some PWID
have negative perceptions of harm reduction practices? Understanding how PWID
perceive harm reduction programing may help tailor programs to meet needs at the local
level, leading reinforced positive outcomes for PWID.
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Identification

Records identified through
database searching
(n = 65)

Included

Eligibility

Screening

Records after duplicates removed
(n = 53)

Records screened
(n = 53)
Full-text articles
assessed for eligibility
(n = 5)

Studies included in
qualitative synthesis
(n = 4)

Records excluded
(n =49)
Not related to perception
of harm reduction
(n=21)
Study conducted outside
of the United States
(n=28)

Full-text articles
excluded, with reasons
(n = 1)
Study conducted outside
of the United States

Figure 1. PRISMA flow diagram showing search results for articles discussing
perceptions of harm reduction among PWID in the United States.
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Table 2
Description and Results of Studies Exploring PWID Perception of Harm Reduction in the United States
Citation

17

Allen, S.T., Grieb, S.M.,
O’Rourke, A., Yoder, R.,
Planchet, E….Sherman,
S.G. (2019).
Understanding the public
health consequences of
suspending a rural syringe
exchange services
program A qualitative
study of the experiences
of people who inject
drugs. Harm Reduction
Journal, 16(33). doi:
10.1186/s12954-0190305-7

Population,
Location
Adult PWID in
Kanawha County,
West Virginia

Study Design

Description

Findings

Qualitative semistructured
interviews
analyzed with an
iterative constant
comparative
technique. Data
were collected in
September 2018.
A convenience
sampling strategy
was used,
although the
authors did not
explicitly state it.

The KanawhaCharleston Health
Department opened a
SEP in December 2015.
Due to community-level
and political upset about
the SEP, the
sociopolitical
environment changed.
This led to unfavorable
laws/regulations for the
SEP, forcing it to operate
outside of best practices.
The SEP ultimately
suspended services due
to these circumstances in
March 2018. This study
explored the public
health implications of the
SEP closure, and
includes data on the
perceptions of SEP as a
harm reduction strategy.

Sixteen male and 11 female
PWID participated in the study
(n=27). The majority (n=21)
utilized the SEP. Participants
described their participation at the
SEP and held a favorable
perception of the harm reduction
strategies used within the
program. Participants described it
as a trustworthy program, and
highlighted positive attributes
including the importance of
disease and overdose prevention.
The study discusses implications
at the public health level due to
the SEP closure. This study
funded by the Bloomberg
American Health Initiative at the
Johns Hopkins Bloomberg School
of Public Health.
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Table 2 (continued).
Citation

18

Baker, L.S., Smith, W.,
Gulley, T., & Tomann,
M.M. (2019). Community
perceptions of
comprehensive harm
reduction programs and
stigma towards people
who inject drugs in rural
Virginia. Journal of
Community Health. doi:
10.1007/s10900-01900732-8

Population,
Location
Adults in
Dickenson County,
Virginia. Sample
includes PWID
and non-PWID.

Study Design

Description

Findings

Cross-sectional,
community-based
participatory
research study
using a Likertscale survey with
one open-ended
question
administered via
the internet or inperson from June
to August 2018.
A convenience
sampling strategy
was used for
recruitment.

Investigators aimed to
assess community
perceptions of harm
reduction programs and
stigma toward PWID in
Dickenson County,
Virginia, which is
considered a rural
community. Assessment
of categorical
perceptions of PWID
(strong v. weak,
deserving v. worthless,
addiction is a disease v.
choice) were compared
to ranked level of
support for harm
reduction programs.

One hundred fifty-three people
participated, and 112 of them
completed the study online. Ten
percent of respondents identified
as PWID (current or former), and
50% knew a PWID friend or
family member. Respondents who
reported high levels of stigma
towards PWID were least likely
to support harm reduction.
Respondents who believed harm
reduction programs could reduce
the spread of infectious disease
expressed a significant, positive
correlation with support for
programs, demonstrating a
positive perception of harm
reduction. This study was
supported with funds from the
Healthy Appalachia Institute at
the University of Virginia’s
College at Wise.
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Table 2 (continued).
Citation
Carlberg-Racich, S.
(2016). Harm reduction
interventions in HIV care:
a qualitative exploration
of patient and provider
perspectives. PeerJ, 4.
Doi: 10.7717/peerj.1932

Population,
Location
HIV care providers
and HIV patients
with active
substance use
disorder in
Chicago, Illinois

Description

Findings

Qualitative
phenomenological
study using semistructured
interviews.
Convenience and
snowball sampling
strategies were
used. Peer
debriefing and
member-checking
were employed.

Harm reduction
strategies may be
employed in clinical
care settings, such as
HIV clinics, but little is
known about how
patients and clinicians
perceive incorporation
of such training into
practice. The
investigator sought to
explore such perceptions
and develop
implications for
practice.

Thirty-one patients and seven
clinicians participated in the
interviews. All patients used
heroin and/or cocaine, but not all
injected. Patients were generally
receptive to receiving harm
reduction counseling in the
clinical setting, and most agreed
provision of sterile drug use
equipment would be helpful.
Some patients (n=16) were not
comfortable disclosing their drug
use to their clinicians due to fear
of being labeled, shame, or
negative messaging. Providers
were supportive of using harm
reduction strategies in clinical
practice, but time constraints and
lack of familiarity were seen as
barriers. Overall, patients who use
drugs were receptive to having
harm reduction counseling and
supplies incorporated into clinical
care. This study was partially
funded by the Sherri Aversa
Memorial Dissertation Fund.
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Study Design
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Table 2 (continued).
Citation

20

Harris, R.E., Richardson,
J., Frasso, R., &
Anderson, E.D. (2018).
Perceptions about
supervised injection
facilities among people
who inject drugs in
Philadelphia.
International Journal of
Drug Policy 52, 56-61.
doi:
10.1016/j.drugpo.2017.11.
005

Population,
Location
PWID and
healthcare
providers recruited
from a SEP in
Philadelphia,
Pennsylvania

Study Design

Description

Findings

Qualitative free
listing ethnographic
exercise and semistructured
interviews were
used. Convenience
sampling and SEP
staff referral served
as recruitment
strategies.

Two studies in the
United States (in San
Francisco and Rhode
Island) demonstrated
quantitative PWID
support for supervised
injection facilities
(SIF). This study aimed
to qualitatively explore
PWID support for such
facilities, and explored
the motivations for
drug injection location
among PWID in
Philadelphia.

Nine men and 10 women
participated in the interview
process (n=19). Forty-two PWID
and 20 healthcare providers
participated in the free listing
exercise. PWID in this study
support SIF as a positive harm
reduction intervention, although
they prefer to inject at home.
They note the importance of
clinical supervision to reduce
overdose death. PWID perceived
SIF as a potential “safe haven,”
where they could perform
injection in a calm environment
without fear of assault or arrest.
PWID perceived SIF value within
the community by reducing
community exposure to discarded
injection equipment. PWID
perceive social and environmental
factors such as homelessness and
distance as influencers on their
degree of SIF use. The authors
did not report a funding source
for this study.

Note: SEP= Syringe Exchange Program. SIF= Supervised Injection Facility.

20

Syringe Exchange Programs
Syringe Exchange Programs (SEP) are based on harm reduction principles where
a non-judgmental approach to the program participant is paramount (Treloar et al., 2016).
They have been active in the United States since 1988 (Des Jarlais et al., 2015; Fernandes
et al., 2017). Syringe Exchange Programs (SEP) services include provision of injecting
supplies such as sterile water, cotton filters, tourniquets, cookers, syringe disposal
containers, and an appropriate syringe selected based on the injector’s needs (i.e. the
quality of their veins), with the expectation of syringes being returned to the site for safe
disposal without re-use or sharing (Hagan, Pouget, & Des Jarlais, 2011). Counseling
includes discussion of safer injection techniques, such as using alcohol swabs before
injecting and using antibiotic ointment and an adhesive bandage afterward; discussion on
infectious disease exposure risk; and the importance of safe syringe disposal (Hagan et
al., 2011). An important aspect of SEP is the ability of the SEP staff, which is often
comprised of certified drug and alcohol counselors or peers who also used drugs, to
identify the aperture (or window of opportunity) for the person who injects drugs to
consider entering addiction treatment, and the level of trust the programs can build with
people who inject drugs (PWID) seeking care (Treloar et al., 2016). Counselors can make
referrals for drug treatment, discuss drug treatment strategies and past experiences, and
help match an addiction care program to the person’s needs.
Disease prevention is a critically important aspect, and many SEP sites offer a
combination of HIV, HCV, and sexually transmitted infection screening for participants,
as recommended by the Centers for Disease Control (CDC, 2012). Syringe exchange
program services are increasingly available in the United States, but not all PWID access
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such programs, or access them inconsistently for a variety of reasons (Davis et al., 2019).
People who use drugs engaging in harm reduction programs have a general understanding
of the public and personal health benefits these programs promote, and are supportive of
them (Bozinoff, Small, Long, DeBeck, & Fast, 2017; Otiashvili et al., 2019).
Best practice guidelines for SEP exist, and cover aspects from effective practices
to community engagement. In order to identify available best practices for SEP, a
systematic review was conducted. PubMed (MEDLINE) was used as the primary
database as it includes a diversity of literature across health and social sciences, including
addiction. Using search terms “syringe exchange program,” or “syringe service
program,” or “needle exchange program,” or “needle supply program,” and “best
practice,” 37 articles were found. Two additional publications were located using a hand
search strategy in an effort to locate resources from professional organizations. Figure 2
displays the PRISMA flow diagram, including reasons for excluding articles. Articles
were included without time limitations, and if they were written in English, and stated
best practices or provided guidelines for SEP services. Table 3 lists specific best practices
from each guidance document.
The most comprehensive guidance on harm reduction appears to be Strike et al.’s
2006 document created with the help of the Ontario Needle Exchange Coordinating
Committee, a representative committee from the Ontario Needle Exchange Network. The
document covers SEP efficacy, factors involved in starting a program, recommendations
for best practices surrounding supply handling and disposal, distribution of equipment,
delivery models, and provision of education (including safer sex and overdose
prevention), social support, medical care, law enforcement relationships, and tools for
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program evaluation. Using the 2006 guidelines as a backbone, Strike and Watson (2017)
modified recommendations to better fit the needs of crack cocaine smokers in terms of
supply needs, and pipe distribution. The New York City Department of Mental Health
and Hygiene 2009 guidance document offers best practice guidelines for SEPs across the
United States. Content includes guiding principles, outlines SEP practices to avoid,
recommendations for data collection and program evaluation, recommendations to
improve SEP access and availability, how to address state paraphernalia laws related to
SEP supplies, and additional recommendations such as encouragement of syringe
pharmacy sales and prescribed syringes. The authors encouraged the Institute of
Medicine to study SEP best practices, and the National Institutes of Health to convene a
consensus panel for the purpose of identifying research gaps. Having best practices for
SEP is as important as recognizing which practices to avoid. Understanding the
challenges of SEP operators and SEP participants face in maximizing best practices while
avoiding potentially damaging practices is critical for PWID as individuals, as well as
ensuring a successful SEP operation.
All three best practice documents consider the importance of having low-barrier
access to sterile drug injecting supplies. Education is a critical piece, including
discussions on safer sex, disease transmission, and safer use practices. The best practice
guidelines also consider program evaluation to be an important administrative component
as a means to track supply distribution and interactions with clients, and to ensure client
needs are being met. The guidance documents discuss the importance of providing a
referral mechanism or actual healthcare in the SEP setting as many PWUD have health
concerns such as abscesses, cellulitis, burns, and more. Linkage to addiction are,
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including opioid substitution treatment, is another common recommendation. None of the

Identification

guidance documents operating costs or detail all budgetary considerations.
Records identified through
reference review and hand
search
(n=2)

Records identified through
database searching
(n = 37)

Included

Eligibility

Screening

Records after duplicates removed
(n = 39)

Records screened
(n = 39)

Records excluded
(n = 32)
Best practices are not
specific to SEP (n=12)
Conference Proceedings
(n=2)
Not relevant to topic
(n=18)

Full-text articles
excluded, with reasons
(n = 4)
Article describes
guidelines process
development, not actual
best practices for SEP
(n=2)
Article describes
methods for assessing
quality indicators of best
practices, not actual best
practices (n=2)

Full-text articles
assessed for eligibility
(n = 7)

Studies included in
qualitative synthesis
(n = 3)

Figure 2. PRISMA flow diagram demonstrating systematic search results for best
practices for syringe exchange programs.
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Table 3
Best Practice Guidelines for Syringe Exchange Programs
Source
Country
Description
Strike, C. & Watson,
Canada
Among people who smoke crack
T.M. (2017). Education
cocaine, a number of negative
and equipment for
health outcomes exist including
people who smoke
oral ulcerations, oral cuts, burns,
crack cocaine in
and increased risk for HIV and
Canada: progress and
HCV. Harm reduction for people
limits. Harm Reduction
who smoke crack has lagged
Journal, 14(1). doi:
behind such programming for
10.1186/212954-017PWID. This work was not funded.
0144-3

25
Strike, C., Leonard, L.,
Millson, M., Anstice,
S., Berkeley, N. &
Medd, E. (2006).
Ontario needle
exchange programs:
Best practice
recommendations.
Toronto: Ontario
Needle Exchange
Coordinating
Committee, 2006.

Canada

This 266-page document, available
in PDF at
http://www.ohrdp.ca/wpcontent/uploads/pdf/Best_Practice
s_Report.pdf, was developed by
the 2006 committee as part of the
Ontario Needle Exchange Network
(ONEN). Roles of ONEN are
wide-spread, and include
education of providers,
communities, and PWUD. This
work was funded by Health
Canada.
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Recommendations
-Provide safer equipment (including stems,
mouthpieces, screens, push sticks)
-Do not require clients to return used equipment
-Provide the quantity requested by the client
-Have both pre-packaged kits and individual pieces of
equipment available
-Integrate programming into existing SEP
-Provide safe disposal options
-Provide other harm reduction supplies (condoms,
lubricant) without quantity limits
-Educate clients on safer use, risks of sharing smoking
supplies, and safer sex
Provide multiple locations for disposal
Brief best practices for SEP (p.39):
-Provide sterile injecting equipment in quantities
requested by clients without requiring them to return
used equipment or limiting the number of new
equipment provided.
-Encourage clients to return used syringes for safe
disposal
-Educate clients about the risk of using non-sterile
supplies

Table 3 (continued).
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Source
New York City
Department of Health
and Mental Hygiene
(NYC DHMH) (2009).
Recommended best
practices for effective
syringe exchange
programs in the United
States. Retrieved from
https://harmreduction.o
rg/wpcontent/uploads/2012/0
1/NYC-SAPConsensusStatement.pdf

Country
United
States

Description
A group of SEP experts convened
to develop this consensus
document outlining best practices
for SEPs, and points out factors
which may limit SEP
effectiveness.

Recommendations
Effective SEPs share the following characteristics:
Low threshold access to services by
-Maximum number of locations and available hours
-Anonymity of participants
-Minimize administrative requirements of participants
Promote secondary exchange
-Train and support peer educators
-Do not limit syringe quantities
Address local PWID population
-Adapt activities and services to local needs
Provide/coordinate health and social services as needed
Include community stakeholders in creating supportive
SEP environment
Practices to Avoid:
-Supplying syringes that may only be used once
-Requiring one-for-one exchange
-Limiting participants to a specific geographic location
-Restricting supply volumes
-Requiring identification of participants
-Requiring unnecessary data collection
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SEP best practice guidance encouraged implementing the least restrictive supply
distribution model possible (NYC DHMH, 2009; Strike et al., 2006). There are multiple
models of SEP equipment distribution. They include a one-for-one exchange, less than
one-for-one, one-for-one plus, and needs-based system of supplying and returning used
syringes. Table 4 provides a brief description of each model. While the protocol of all
SEPs involves supply of syringes, provision of other drug injecting equipment varies
from program-to-program. For example, Bixler et al., (2018) evaluated SEPs in
Kentucky, West Virginia, and North Carolina and found wide variation in services
beyond supplying sterile syringes. Kentucky had the most operating programs with
access to injecting supplies (such as cookers, filters, water, alcohol swabs, tourniquets),
while West Virginia and Kentucky were nearly equal on the percentage of programs
supporting HIV and HCV screening, reproductive planning, and education. Regardless of
the syringe distribution model used, PWID have access to sterile syringes when visiting
SEP (Bixler et al., 2blu018; Bluthenthal et al., 2007).
Table 4
Syringe Exchange Program Distribution Models
Model
Program Description
One-for-one exchange
For each used syringe returned, participants may replace it
with a sterile one.
Less than one-for-one
exchange

Like one-for-one, this program requires an exchange of
used-for-new syringes, but the syringes must originate
from the SEP. For example, a syringe from a pharmacy can
be returned after use, but it will not count towards a sterile
replacement because it did not come from the specific SEP.

One-for-one plus
exchange

Participants may exchange the number of syringes returned
and take an additional pre-determined amount in an effort
to build up a stable supply of sterile equipment between
SEP visits. For example, a participant may return 20
syringes and have 30 provided in exchange.
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Table 4 (continued).
Model

Program Description

Needs-based

Participants may obtain the number of sterile syringes
needed without regard to the number of syringes returned.
Participants are not limited on the frequency of their visits.
This approach is considered best practice.

Note: (Bluthenthal et al., 2007; Sherman et al., 2015).
In Kentucky, many SEP programs are limited to a one-for-one syringe exchange,
despite the fact this is not considered best practice (NYC DHMH, 2009; Sherman et al.,
2015). This model may lead to syringe reuse and sharing among people unable to return
an adequate number of used syringes (KDPH, 2015; NYC DHMH, 2009). In cities like
Vancouver and San Francisco, where transitions from a one-for-one model to a needsbased model of syringe distribution occurred, there were increases in SEP participation,
the number of syringes distributed and returned, and an increase in new SEP clients
(Sherman et al., 2015). However, a one-for-one model may serve as a stepping stone for
communities initially reluctant to provide SEP services, and those with budget limitations
(KDPH, 2015). Ultimately, SEPs provide sterile injection supplies to the PWID
community, but the impact on reduction in HCV/HIV incidence may be limited due to
continued syringe sharing and misuse behavior and the one-for-one approach does not
adequately cover PWID needs (Bluthenthal et al., 2007).
SEPs operating under a one-for-one plus model distribute syringes based on the
number returned, but supply an additional set quantity per visit. This model is the
intermediary between a strict one-for-one policy and a needs-based model (Bluthenthal et
al., 2007). SEPs using a needs-based approach may serve as an important aspect in
increasing SEP reach through secondary exchange (Brothers, 2016). The Centers for
Disease Control (CDC) recommends a sterile syringe be used for each injection, and a
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needs-based model of syringe exchange ensures PWID have a sterile syringe for each
injection (2019).
What is happening in Kentucky’s Syringe Exchange Programs?
The United States has seen a surge in injection drug use and new cases of
hepatitis C virus (HCV) infection since 2004, with sharp increases in both beginning in
2010 (Campbell et al., 2017; Zibbell et al., 2018; J. E. Zibbell et al., 2015). Outbreaks
and clusters of human immunodeficiency virus (HIV) infection, which are also associated
with injection drug use, have occurred across the United States during the same time
frame (Bradley et al., 2019; Moorman, Krolikowski, Mathis, & Pack, 2018; Peters et al.,
2016). One of the most serious HIV outbreaks occurred in Scott County, Indiana in 20142015, where 181 people were diagnosed with HIV (Peters et al., 2016). Among them, 167
(92.3%) were co-infected with HCV. Nearly 88% of the cases were directly tied to
injection opioids (Peters et al., 2016). The Scott County HIV/HCV outbreak served as a
wake-up call for the United States to recognize the risk of acquiring infectious diseases
among vulnerable PWID populations, especially in Appalachia, where SEP had been
illegal (Des Jarlais et al., 2015; Van Handel et al., 2016).
In response to the serious HIV/HCV outbreak in Scott County, Indiana and
subsequent recognition of Kentucky’s vulnerability to experiencing a similar event, the
Kentucky state legislature passed an emergency provision legalizing SEP in March 2015
(Bixler et al., 2018; Goodin, Fallin-Bennett, Green, & Freeman, 2018). The first SEP to
begin operating in Kentucky opened on June 5, 2015 in Louisville, where it continues to
operate as the state’s largest and most comprehensive SEP. By October 28, 2019, 69
SEPs had been authorized or became operational in Kentucky, and Kentucky has more
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SEPs than any other state (see Figure 3). Each SEP required the approval of local (city),
county, and state officials are under the jurisdiction of local health departments or their
partners (Bixler et al., 2018).

Figure 3. Kentucky map showing location by county of SEP in operation or approved as
of August 2, 2019. Counties in green (n=54) are among the top 220 counties in the
United States considered vulnerable to an HIV outbreak, similar to that seen in Scott
County, Indiana (KCHFS, 2019).
Kentucky SEPs are required to track the number of syringes distributed and
returned, basic participant demographic factors, type of substance(s) injected, HIV and
HCV screening tests, and if available: naloxone education and distribution, fentanyl test
strip distribution and results, and linkage to social, addiction, or healthcare services. Over
time, the Louisville Metro Department of Public Health and Wellness SEP, which uses a
one-for-one plus syringe distribution model, began receiving participant reports of
syringe sharing and used equipment reuse in their efforts to collect required data (W.
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Crabtree, personal communication, January 12, 2017). Syringes represent a common
piece of equipment shared or reused; however, cookers, cotton filters, and tourniquets are
also susceptible to misuse and may spread infectious disease (Kim, Jin, McFarland, &
Raymond, 2015; Palmateer et al., 2014). Although many SEPs across the United States
support sharing of sterile equipment through peers (secondary exchange), it is not a
formally endorsed practice at any of Kentucky’s SEPs (Behrends et al., 2017).
The LMDPHW SEP promotes weekly visits through their efforts to supply
participants with enough injecting equipment to last one week. However, participants are
not required to return at any particular time interval. For first-time participants who do
not have any used syringes to dispose of, 50 syringes are distributed along with all other
needed equipment according to protocol (T. Nunez, personal communication, July 10,
2019). The participant has the option to return as many times as needed, as frequently as
needed, to build up their syringe supply to last one week or more. Anyone returning
syringes for disposal may take that number of sterile syringes, plus 20 if desired. If a
returning participant is not able to exchange any used syringes, up to 20 syringes are
distributed with the expectation they will begin to build their sterile supply once more
through return visits. Notably, choice of substance and degree of dependency impacts the
daily frequency of drug injection. PWID may inject opioids, cocaine, methamphetamine
or other substance recreationally (less than once per week), and need very few syringes.
However, those dependent on cocaine may need 20 or more syringes per day. At the
LMDPHW SEP, 62.8% of participants reported injecting five or more times each day
(Cave, 2019). Some participants exchange more than 400 syringes at their weekly visits,
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suggesting that they are not only acquiring supplies for their own use, but supplies for
others (Cave, 2019).
Overall, SEP programs in Kentucky follow most of the best practices for such
programs as described in the New York City guidance (2009). They provide client
anonymity, an assortment of sterile supplies (not just syringes), education, infectious
disease testing, linkage to healthcare, social services, and addiction care, and make use of
harm reduction principles in their approach to PWID in the programs. One of the largest
gaps between SEP best practices and SEP operations in Kentucky is the distribution
quantity limitation where participants may not receive enough sterile supplies. Although
there is no limit on the number of visits a client can make to the SEP, this quantity
limitation per visit may be a major barrier in ensuring clients are not sharing or reusing
supplies. The social determinants of health model may help identify SEP participation
barriers, and provide a framework for SEPs to positively adapt their programs to improve
access.
Social Determinants of Health Model
The social determinants of health (SDOH) are a group of factors that influence the
health, well-being, and longevity of people and has been used worldwide as a framework
for improving population health and reducing health disparities. Based primarily on the
work of Sir Michael Marmot, the SDOH were recognized as overarching influencers on
individual health, and health outcomes and that these influencers occur across a social
spectrum (Marmot & Wilkinson, 2006). That is, health influences are not merely a result
of race, ethnicity, genetics, gender or individual behavior. Marmot recognized a
multitude of factors that influence health, and developed the SDOH model to help enable
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action strategies to improve the morbidity and mortality of populations (2006). Marmot
and Wilkinson’s (2006) work linked social structure to health through a number of
factors, and they presented applied examples and supporting evidence about how such
factors could be influenced by experiences in early childhood, culture, socioeconomic
factors and genetics (Marmot & Wilkinson, 2006). Figure 4 presents a social
determinants of health model.

Figure 4. Social determinants of health demonstrating the link between social structure and
pathways which may lead to health or disease (Brunner & Marmot, 2006, p. 9).
Over time, the model has been refined and adapted. The World Health
Organization (WHO) (2019) describes SDOH as
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…the conditions in which people are born, grow, live, work, and age. These
circumstances are shaped by the distribution of money, power, and resources at
global, national and local levels. The social determinants of health are mostly
responsible for health inequities- the unfair and unavoidable differences in health
status seen within and between countries.
The World Health Organization (WHO) identifies key concepts within SDOH of
economic stability, education, health and healthcare, neighborhood environments, and
social contexts that include employment conditions, social inclusion, public health
programs, women and gender equity, early childhood development, globalization, health
systems, and measurement and evidence, and urbanization. Each of these key concepts
are described in detail through publications and policy interventions that provide
blueprints for communities (WHO, 2019).
The United States Department of Health and Human Services (HHS) Healthy
People 2020 health objectives use five SDOH factors: economic stability, education,
health and healthcare, neighborhood and built environment, and social and community
contexts to frame objectives that lead to social and physical environments that promote
good health (HHS, 2014). Each health determinant contains a subset of factors that may
influence an individual’s chance for optimal health (see Table 5).
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Table 5
Social Determinants of Health and Key Influencing Factors for Healthy People 2020
Social Determinant
Factors
Economic stability
Employment, food insecurity, housing instability, poverty
Education

Early childhood education/development, enrollment in higher
education, high school graduation, language and literacy

Health/Healthcare

Access to health care and primary care, health literacy

Neighborhood/ built
environment

Access to foods that support health eating patterns, crime and
violence, environmental conditions, quality of housing

Social/ Community
contexts

Civic participation, discrimination, incarceration, social
cohesion

Note: Adapted from Healthy People 2020 (HHS, 2014).
The SDOH are easily applied to PWID. Van Handel et al. (2016) noted how the
PWID of Scott County, Indiana suffered from unemployment and poverty, had low
educational attainment, and had poor life expectancy. People who inject drugs are often
subject to incarceration, which may further increase their risk of acquiring HIV and/or
HCV (Stone et al., 2018). Low health literacy among PWID is common, especially when
trying to understand how their substance use may impact their liver health (Marshall,
Grebely, Dore, & Treloar, 2017). In the healthcare setting, PWID are often stigmatized
and discriminated against (Bartlett, Brown, Shattell, Wright, & Lewallen, 2013; Couto,
Cruz, Salom, Maravilla, & Alati, 2018).
The SDOH model has been used by nurses caring for PWUD in an opioid
substitution program in New Bedford, Massachusetts, an area similarly affected by both
HCV and opioid epidemics (Gadbois, Chin, & Dalphonse, 2016) like Kentucky. The
authors recognized limited access to housing, food, and primary healthcare were
substantial barriers to improving the health of PWUD in an addiction care program. The
authors used such SDOH as a tool for developing a quality improvement program that
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involved nurses and multidisciplinary staff at an urban hospital. Outcomes demonstrated
improved assessment of SDOH and care coordination for people in the program
(Gadbois, Chin, & Dalphonse, 2016).
Applying the SDOH model in future research may help us understand the driving
forces behind SEP participant’s inconsistent use of sterile injecting equipment with each
injection episode. The SDOH disparities that may lead some to injection drug use may be
the same disparities that limit full use of SEP and adoption of harm reduction strategies.
Assessing, addressing, and mitigating potential factors that may be uncovered through
research will support PWID to more fully utilize SEP services, thus, reducing the risk of
additional spread of HIV, HCV, and other negative health outcomes. It may also help
facilitate care coordination between the SEP and other community services.
Conclusion
Understanding why PWID engaging in SEP services are not consistently using
sterile drug injection supplies for 100% of injection events needs to be explored. It is
clear that sharing or reusing old injecting equipment propagates infectious disease,
among other health-related and social harms. Kentucky is leading the nation in new cases
of HCV infections, and is at risk for having simultaneous clusters or a widespread
outbreak of HIV and HCV co-infection in PWID (Van Handel et al., 2016). Kentuckians
now have access to SEP throughout the Commonwealth, but there continues to be syringe
and drug injection equipment reuse and sharing among PWID participation in such
programs. It is unclear if this dilemma is related to lack of best practice in syringe
distribution models in Kentucky’s SEPs, where the majority of programs operate under a
one-for-one model. Research is warranted to explore the degree of drug equipment
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misuse among SEP clients, and to understand what factors contribute to such behavior.
The SDOH model may offer some explanation as to why PWID continue to share or
reuse drug injecting equipment. The SDOH model may provide a framework for future
action in addressing the problem.
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CHAPTER III
EXAMINING SYRINGE AND INJECTING EQUIPMENT SHARING AND REUSE
AMONG PEOPLE WHO INJECT DRUGS PARTICIPATING IN A SYRINGE
EXCHANGE PROGRAM
Overview
Introduction: People Who Inject Drugs (PWID) are at risk for negative health
consequences. Harm reduction strategies like syringe exchange programs (SEP) help
reduce consequences like skin and soft tissue infections, infectious disease, and
endocarditis through provision of sterile injecting supplies and education. These services
benefit PWID, yet some SEP participants continue to share or reuse (misuse) drug
injecting equipment. Although much is known about the behaviors and motivations for
PWID to misuse equipment outside of SEPs, little is known about the factors influencing
those who utilize SEP services who continue misuse injecting equipment. This study
aimed to examine the prevalence of injection equipment misuse with others, personal
injection equipment reuse, and to describe the factors leading to equipment misuse
among people participating in SEP. Methods: The study utilized a two-phase approach.
A cross-sectional survey was used to estimate the prevalence of injecting equipment
misuse. Qualitative interviews explored behaviors and motivations leading to injection
equipment misuse. Both strategies utilized convenience sampling at a single urban SEP in
an Appalachian state. Results: There were 111 surveys were collected. Participants were
21-68 years old, with mean age of 37.8 years (SD=10.7). Most were male (59.5%, n=66);
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87.4% (n=97) were white; 45.9% (n=51) visited SEP monthly; and 33.3% (n=37) weekly.
The majority (69.4%, n=77) reported providing used equipment to others. Nearly 30%
(n=32) reported reusing their old equipment, and 37.8% (n=42) reported using equipment
that was used by another person. Fifteen individuals participated in interviews. The
average age was 39 (SD=11.6; range=28-60); 53% (n=8) were male, 40% (n=6) were
female, one was transgender; and 87% were white. Four themes uncovered
behavioral/situational factors associated with drug injection equipment misuse: sterile
supply stability issues; high-risk behaviors or attitudes; having the right equipment at the
right time; and trying to be safe. Conclusion: Injection equipment sharing and reuse is
common, even among people participating in a SEP. There are reasons for sharing and
reuse that are related to social determinants of health. Multiple opportunities exist for
SEPs to develop interventions and strategies to reduce the prevalence of injecting
equipment misuse.
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Background and Significance
People who inject drugs are at highest risk for acquiring and spreading hepatitis C
virus (HCV) infections, representing up to 80% of HCV infection cases in the United
States (Martin, Vickerman, Dore, & Hickman, 2015; Zibbell et al., 2018). Through harm
reduction practices such as syringe exchange programs (SEP), also known as needle
exchange programs and syringe service programs, participants are educated on best
practices for reducing the risk of infection and other harms, and provided with sterile
injecting supplies. Despite provision of free sterile injecting supplies and education, there
exists some degree of syringe re-use or sharing among SEP participants (Bluthenthal et
al., 2004; Bozinoff, Small, Long, DeBeck, & Fast, 2017; Ksobiech, 2006). Such behavior
is counter-productive to SEPs and harm reduction as a whole because it allows for spread
of infectious disease, skin and soft tissue infections, or blood stream infections. Although
behaviors of people who inject drugs (PWID) are well described and the need for harm
reduction through SEP is clearly supported in literature, little is known about the factors
and behaviors influencing SEP participants who might continue to share or re-use
syringes, and the prevalence of such behavior (Allen, Ruiz, Roess, & Jones, 2015;
Dunleavy et al., 2017; Hagan, Pouget, & Des Jarlais, 2011; Hesamizadeh, Sharafi,
Rezaee-Zavareh, Behnava, & Alavian, 2016; Mateu-Gelabert et al., 2014).
This risky sharing and re-use of supply behavior occurs within all PWID
communities. Ksobiech (2006) conducted a meta-analysis demonstrating syringe sharing
behaviors were reduced among SEP participants compared to those who do not
participate, but the prevalence of syringe sharing was not reported in this analysis. In a
broader search conducted in the fall of 2018 using PubMed (MEDLINE), CINAHL,
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EMBASE, and PsychINFO, including worldwide articles using search terms “people who
inject drugs”, “syringe exchange program,” “needle exchange,” “syringe or needle
misuse”, “re-use”, and “sharing”, only one article was found (Kim, Jin, McFarland &
Raymond, 2015). Kim et al. (2015) determined the rate of unsafe injecting practices (such
as using a syringe previously used by another person, 34.2% [95% CI 24.2-45.2] in 2005
to 12.5% [95% CI 7.5-18.6] in 2012, p<0.001, n=570) had declined, and rates of syringe
acquisition from pharmacies (17.8% in 2005 to 32.1% in 2012, p<0.001) or SEP (80.7%
in 2009 to 86.5% in 2012, p<0.022, n=570) had increased. Although some literature
discusses Secondary Syringe Exchange, which is a practice of visiting SEP to acquire
equipment and education to be distributed to others outside of the program (Behrends, Li
& Gibson, 2017), no studies could be found that focused on behavioral factors associated
with used syringe sharing and personal reuse of equipment by SEP participants
completed within the past twenty years.
The purpose of this research was to explore the motivations and behaviors of
PWID using SEP in a Southern state who share new or used equipment, or re-use
(hereafter, misuse) syringes and drug injection equipment. Drug injection equipment
includes syringes, cookers, filters/cotton, sterile water, and tourniquets. The Specific
Aims are: 1) to examine the daily, weekly, and monthly prevalence of syringe and
equipment reuse and sharing among PWID participating in SEP; 2) to describe the daily,
weekly, and monthly personal syringe re-use prevalence; and 3) to identify behaviors and
motivations leading SEP participants to misuse SEP-provided syringe and/or injecting
equipment.
Theoretical Framework
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The behaviors of many individuals who inject drugs may not reflect application of
knowledge about the risks of acquiring HIV or HCV infection as a consequence of
sharing injection equipment or poor sanitation techniques despite availability of SEP and
sterile syringe supplies through pharmacies (Golub et al., 2007; Kim et al., 2015;
Palmateer et al., 2014). Furthermore, PWID with access to SEP services may not
exclusively obtain syringes from a sterile source such as SEP or a pharmacy; they may
buy them from drug dealers, share with friends, or use a diabetic’s discarded insulin
syringes (Wejnert et al., 2016). This behavior may be due to a multitude of factors that
have not been previously identified due to the paucity of research regarding PWID
engaged in SEP services. Although some hypotheses have been identified such as
defensive behavior in which PWID may prioritize immediate injection to avoid
withdrawal symptoms, or social norms that encourage sharing a drug preparation among
multiple users in a group setting (Bozinoff et al., 2017; Golub et al., 2007). The lack of
research warrants the use of a health model that allows for a complex view of factors that
may serve as barriers or facilitators of these behaviors. Therefore, applying a model
focused on the social determinants of health (SDOH) is appropriate.
The SDOH model was developed by Marmot in the 1990s. The SDOH model
described the ways in which economic and social standing could influence health and
health outcomes among individuals and populations. Marmot and Wilkinson’s (2006)
SDOH model included determinants such as social structure, social environment,
employment, health behaviors, and material factors while considering the influence of
early life experiences, genetics, and culture in the overall health or disease status of
populations. This socioeconomic model has been adapted across the world, including the
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World Health Organization (WHO) which uses the SDOH as a guide to impact the health
of diverse populations, even nations. The United States Department of Health and Human
Services (DHHS) adopted a list of five determinants on which the Healthy People 2020
health objectives are based. Both the WHO and DHHS models break down the
determinants into factors, which can be used as assessment tools and a framework for
policy development. Table 1 displays the DHHS disparities and factors.
Table 1
Social Determinants of Health and Key Influencing Factors for Healthy People 2020
Social Determinant
Factors
Economic stability
Employment, food insecurity, housing instability poverty
Education

Early childhood education/development, enrollment in higher
education, high school graduation, language and literacy

Health/Healthcare

Access to health care and primary care, health literacy

Neighborhood/ built
environment

Access to foods that support health eating patterns, crime and
violence, environmental conditions, quality of housing

Social/ Community
contexts

Civic participation, discrimination, incarceration, social
cohesion

Note: Adapted from Healthy People 2020 (DHHS, 2014).
For the purposes of this research, the DHHS (2014) SDOH model used in Healthy
People 2020 was applied to the findings. This SDOH model is specific to the United
States, and the objectives related to SDOH positively impact PWID (see Appendix A).
Exploration of the factors within the five social determinants may hold the most potential
for understanding the risky PWID behavior as it relates to decisions about syringe and
drug injecting equipment misuse, and also serve as a framework for the development of
future interventions.
Methods
Study Design
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This was a two-phase study which consisted of quantitative (survey) and
qualitative (individual interview) approaches. A two-phase approach was best strategy to
quantitatively estimate the frequency of the behaviors of interest, to qualitatively uncover
reasons for them, and to avoid the problem of overlooking important evidence while
increasing understanding of the problem (Pluye & Hong, 2014). Cross-sectional surveys
were used to estimate frequency of behaviors in a given population, and was considered
the most appropriate approach to measure drug injecting equipment misuse in this
sample. Cross-sectional surveys are a common quantitative approach to assessing
prevalence, and may also be used for measuring attitudes, validation studies for different
instruments, and assessing reliability (Kesmodel, 2018).
Qualitative methods, particularly a focused ethnography approach, has been used to
study people who use drugs worldwide, and have examined multiple types of illicit drugs
and/or alcohol, and routes of administration (Ambrogne, 1999; Dilkes-Frayne, 2016;
Fast, Kerr, Wood, & Small, 2014; McNeil, Kerr, Lampkin, & Small, 2015; Pagano et al.,
2018; Wall, 2015). Studies have centered around identifying barriers for drug users
seeking harm reduction (McNeil et al., 2015), how networks of drug use are created and
social norms developed at multi-day music festivals (Dilkes-Frayne, 2016), and how
people of an ethnic minority who use drugs support each other in addiction treatment
(Pagano et al., 2018). Focused ethnography intends to uncover reasons for behaviors,
problems with existing programs, and potential solutions to such problems through
“mapping of the cognitive world of a culture; a cultures’ shared meanings, semantic
rules” (Polit & Beck, 2017, p.249; Rashid, Hodgson, & Luig, 2019; Wall, 2015).
Interpretation of data resources, such as interviews, photos and field observations help
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researchers form the response to the question, “What is happening here?” amongst a
culture or subculture (Wall, 2015).
Setting
The study was conducted within a mid-sized metropolitan city in the southeastern
United States with a population of 602,000. This community is served by the Syringe
Exchange Program. The metropolitan Syringe Exchange Program (SEP) opened in June
2015. From opening through April 2018, the SEP served more than 15,000 unique
clients. Table 2 displays demographic details for the SEP participants. In February 2017,
the SEP staff informally surveyed participants and found 29% shared syringes (n=497; Y.
Chen, personal communication, 2018).
Table 2
Syringe Exchange Program Participant Demographics for All Clients 6/10/15 to 4/30/18
Number Percent
Clients
Total Clients
15,325
Return Clients
6,834
44.59
Age (years)

17-29
30-39
40-49
50-59
60+

3,443
4,387
1,834
703
191

32.61
41.55
17.37
6.66
1.81

Gender

Female
Male
Transgender - ID Female
Transgender - ID Male

3,945
6,291
18
17

38.41
61.25
0.18
0.17

9,351
380
606
5

90.42
3.67
5.86
0.05

Sex Orientation Straight/Heterosexual
Gay/Lesbian
Bisexual
Questioning
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Table 2 (continued).
Number
9,589
469
89
12
15
190

Percent
92.52
4.53
0.86
0.12
0.14
1.83

Race

White
Black/African American
Native American
Pacific Islander
Asian
Other

Hispanic

Yes
No

248
10,118

2.44
97.59

Employed

Yes
No

3,452
6,897

33.36
66.64

Medicaid
Medicare
Private/Commercial
Other
Uninsured

5,944
348
1,140
72
2,796

56.21
3.29
10.78
0.68
26.44

Heroin
Other Opioids
Cocaine
Methamphetamine
Methadone
Suboxone
Other Drugs

8,446
370
314
3,202
9
10
183

79.88
3.50
2.97
30.28
0.09
0.09
1.73

Insurance

Drug(s) Used

Drug Use Frequency 1 or 2
1,430
13.52
Per Day
3 or 4
2,500
23.64
5 or more
6,644
62.83
Note. Unpublished data provided courtesy of the staff of the SEP. The SEP received
anecdotal reports from PWID using their services that they are sharing or reusing
syringes and supplies (M. LaRocco and W. Crabtree, personal communication, January
16, 2017). Drug(s) used does not equal 100% as some participants may report
simultaneous heroin and methamphetamine use.
Projection of human subjects.
The University Institutional Review Board reviewed and approved this study. A
waiver of informed consent was approved for quantitative survey participants; full
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informed consent was required for interviews. Pseudonyms were used for consent
signatures. A National Institutes of Health Certificate of Confidentiality was approved for
participants in the qualitative interviews. Both quantitative survey and qualitative
interview participants remained anonymous to the investigator.
Sample
Inclusion criteria for the quantitative portion of this study were as follows:
subjects must be a SEP participant (having visited the SEP at least once), age 18 years or
older, a current injection drug user, agreeable to participation, and had not previously
taken the survey. They were excluded from participation if they were under 18 years,
even if they were an emancipated minor, had taken the survey previously, or if they could
not read or understand English. Subjects completed the self-administered survey with an
investigator nearby to clarify any questions as needed.
For the qualitative interviews, subjects were eligible to participate if they were a
SEP participant who reported at least monthly attendance over a six-month period, was
aged 18 years or older, able to provide informed consent, a current injection drug user
with at least six months of reported injection drug use experience, and any reported
history of syringe misuse. Participants were eligible even if they were recreational drug
users who did not inject on a regular basis. Subjects were excluded if they were under age
18, unwilling to be audio-recorded, could not speak or understand English, or unwilling
to provide informed consent. Subjects completing surveys could be included in the
interviews, and no link was made between the subject’s survey and interview.
Recruitment.
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From February 13 through May 8, 2019, a convenience sample of subjects
visiting in a metropolitan syringe exchange program were invited to complete the eightitem survey. Potential subjects were approached by the investigator as they waited for
SEP services. After a brief introduction and explanation of the study, participants
reviewed key study information, including study purpose, benefits/risks of participation,
and alternatives to participation (preamble consent) and decided if they wished to
participate by completing the survey, or declining. Surveys were self-administered on a
single sheet of paper and took two-to-three minutes to complete.
Interview participants were introduced to the investigator by SEP staff or were
recruited as they waited for SEP services. After the investigator introduced herself,
potential participants were taken to a private area of the SEP where informed consent was
completed. Subjects completing the consent were interviewed using an interview guide
containing questions addressing equipment procurement, motivation and situational
factors leading to supply sharing, and questions surrounding supply reuse. The interviews
lasted 15-30 minutes each. Interview subjects were recruited until the newest subjects
were consistently reporting experiences similar to previous subjects (data saturation).
Field notes, observations, photographs taken within the SEP, and printed materials
available in the SEP were collected and reviewed per the focused ethnography guidelines
of Polit & Beck (2017, p.333).
Study Procedures
Cross-sectional surveys were used to quantitatively describe the frequency of
personal drug injecting equipment reuse, and sharing of new and used drug injecting
equipment to fulfill aims one and two of the study. The survey was modeled after an
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informal survey the SEP had distributed to participants in February 2017. The
investigator refined the survey based on content expert input and SEP participant
feedback. The eight-item paper survey consisted of multiple choice and a fill-in-the-blank
response for age (see Appendix D). Table 3 defines frequencies of behaviors, as listed on
the survey and use for analysis purposes. Potential participants were approached face-toface by the investigator within the SEP and invited to participate in the study. Those
agreeing to participate reviewed the consent (Appendix E) with the investigator. Any
questions potential participants had about participating in the study were answered. Those
agreeing to take part in the study completed the survey on their own.
Table 3
Behavior Frequency Definitions
Never
The participant has never engaged in the specified behavior.
Less Than Monthly

The behavior occurs less than once per month.

Monthly

The behavior occurs 1-3 times most months

Weekly

The behavior occurs 1-4 times most weeks

Daily

The behavior occurs 5-7 times most weeks

One-time semi-structured interviews qualitatively addressed factors and
motivations around syringe misuse behavior. Interview questions were open-ended and
conducted one-on-one with the author. Like the quantitative survey, interview questions
were developed by the investigators and refined by a content expert (see Appendix C).
These focused ethnography questions explored the culture and environment surrounding
sterile drug supply acquisition, use, and reuse. Two pilot interviews were conducted with
SEP participants prior to formal data collection to ensure clarity of questioning from a
participant perspective, and to assist the investigator in developing interview skills. All
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interviews were conducted face-to-face in a private room within the SEP over 15-30
minutes. The investigator did not have a prior relationship with interview participants;
participants were informed the interview was part of the author’s dissertation process
before informed consent was completed.
Data Analysis
Quantitative analysis.
Quantitative data were analyzed using SPSS version 25.0 (IBM, Armonk, NY).
Descriptive statistics explored demographic characteristics such as age, gender, ethnicity,
and frequency of SEP equipment misuse. Frequency of misuse were collapsed into binary
variables (ever and never) to avoid small cells. Further analysis explored groups using
Cochran-Mantel-Haenszel tests to detect differences between age and gender across drug
injecting equipment sharing and reuse.
Qualitative analysis.
For qualitative analysis, interviews were transcribed using NVivo Transcribe
(QSR International, Melbourne, Australia) then verified by the investigator for accuracy.
Qualitative data management was facilitated with the use NVivo 12 Plus (QSR
International, Melbourne Australia). Transcripts were not shared with participants due to
the need to preserve their anonymity and logistical difficulty setting appointments for
such a purpose. Transcripts were coded line-by-line using an open-coding strategy to
identify common categories and concepts that may help explain the subculture of people
who use drugs who participate in a syringe exchange program. Coding was an iterative
process, with initial codes such as equipment cleaning, transportation problems, avoiding
withdrawal, and protection of anonymity identified as important factors. Open coding
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allows investigators to label concepts and define categories based on properties or
dimensions in text (Khandkar, n.d.). A second reader helped validate initial codes for
investigator triangulation (Rashid, Hodgson, & Luig, 2019). Secondary coding grouped
codes together into themes (Polit & Beck, 2017, pp 574-579) which describe the culture
surrounding syringe and injection equipment misuse.
Results
Quantitative Sample Characteristics
There were 111 individuals who completed the survey. Table 4 displays
demographics and overview of syringe misuse behaviors. The age range for survey
participants was 21 to 68 years with mean age of 37.7 (SD=10.7) and median of 36 years.
Table 4
Descriptive Statistics and Estimates of Syringe Misuse Behaviors for Survey Participants
Survey Item
Frequency
Binary
(%)
Frequency (%)
Gender, n=111
Male
66 (59.5)
Female
45 (40.5)
Race/Ethnicity, n=110
White, non-Hispanic
Black, non-Hispanic
Hispanic/Latino/Latina
Other
Missing

97 (87.4)
9 (8.1)
0
4 (3.6)
1

Visit Frequency, n=106
First Time
Less Than Once Per Month
Monthly
Weekly
Daily
Missing

5 (4.5)
10 (9.0)
51 (45.9)
37 (33.3)
3 (2.7)
5 (4.5)
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Table 4 (continued).
Survey Item

Frequency
(%)

Binary
Frequency (%)

Provide Used Equipment to Others, n=111
Never
Less Than Once Per Month
Monthly
Weekly
Daily

77 (69.4)
20 (18.0)
4 (3.6)
3 (2.7)
7 (6.3)

Never: 77 (69.4)
Ever: 34 (30.6)

Provide New Equipment to Others, n=109
Never
Less Than Once Per Month
Monthly
Weekly
Daily
Missing

46 (41.4)
16 (14.4)
19 (17.1)
17 (15.3)
11 (9.9)
2 (1.8)

Never: 46 (42.2)
Ever: 63 (57.8)

Personal Reuse, n=110
Never
Less Than Once Per Month
Monthly
Weekly
Daily
Missing

32 (28.8)
16 (14.4)
26 (23.4)
18 (16.2)
18 (16.2)
1 (1.0)

Never: 32 (29.0)
Ever: 78 (70.9)

Receptive Reuse, n=111
Never
Less Than Once Per Month
Monthly
Weekly
Daily

69 (62.2)
5 (4.5)
13 (11.7)
6 (5.4)
18 (16.2)

Never: 69 (62.2)
Ever: 42 (37.8)
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Quantitative Findings
Sharing of new syringe and injection equipment among SEP participants was
common (n=63, 57.8%) with 28 (25.7 %) reporting the sharing of new supplies with
others on a daily or weekly basis. Reuse of personally-used drug injecting equipment was
the most common misuse behavior (n=78, 70.9%), with up to 32.7% (n=36) of
participants reusing equipment on a daily or weekly basis. Reuse of equipment obtained
from another individual was reported by 42 (37.8%) survey participants, 30 of whom
were male. Sharing of used syringes was reported by 34 (30.6%). A higher proportion of
males under 30 years of age reported using injection drug equipment that was previously
used by another person (63%, n=19) compared to women, regardless of age (31.3%, n=16
for women under 30 and 27.6%, n=29 for women 30 years and older), and older men
(40.4%, n=47). Overall, syringe and injection equipment misuse was a familiar activity to
many SEP participants. Table 5 displays syringe misuse prevalence by age and gender,
where no particular form of syringe misuse was significant when stratifying across age
and gender.
Table 5
Bivariate analysis of syringe misuse behaviors stratified by age and gender
Variable
Gender Age Never Ever Total
Chi
DF
(years)
Square
Receptive Reuse
Male ≤ 30
7
12
19
1.373
1
>30
29
18
47
Female ≤ 30
12
4
16
Personal Reuse

>30

20

9

29

Male

≤ 30
>30

3
15

16
31

19
46

Female

≤ 30
>30

6
7

10
22

16
29

53

0.162

1

p-value
0.241

0.687

Table 5 (continued.)
Variable
Sharing Used

Gender

Age Never Ever
(years)
Male ≤ 30
12
7
>30
33
14
Female ≤ 30
11
5
>30
21
8

Total
19
47

DF

p-value

1

0.553

0.004

1

0.948

16
29

Male

≤ 30
>30

6
23

12
23

18
46

Female

≤ 30
>30

8
8

8
21

16
29

Sharing New

Chi
Square
0.351

Qualitative Sample Characteristics
Interview participants (n=15) ranged in age from 28 to 60 years; eight were male
(53%), six were female (40%), and one was male-to-female transgender (7%). All were
Caucasian (n=13, 87%) except for one African American and one Hispanic. Seven (47%)
participants self-disclosed a positive HIV or HCV infection status.
Qualitative Findings
Line-by-line coding produced 54 codes on the first reading of transcripts. Through
re-reading and iteration, initial coding was reduced to 35 concepts. The concepts were
used to develop four themes that help explain syringe and injection equipment misuse
among people in the SEP. Experiencing sterile supply stability issues and having a highrisk behavior/attitude were associated with motivations and behaviors or situations that
made sharing or reusing old equipment likely. Having the proper injecting equipment and
trying to be safe were themes associated with reduced equipment misuse behavior and
improved motivation to use only sterile supplies. Major concepts within these themes and
their related SDOH are listed in Table 6.
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Table 6
Major Themes and Associated Social Determinants of Health
Theme
Behavioral, Situational, or
Related Social
Motivational Concept
Determinant(s)
Sterile supply
-Transportation problems (n=4)
Economic stability
stability issues
-Problems with supply limitations
Health and healthcare
(n=3)
Health and healthcare
-Limited SEP locations/hours (n=4)
Community context
-Fear of arrest (n=3)
High risk
behaviors or
attitudes

Having the
right equipment
at the right time

Trying to be
safe

-Saving drugs for later use (n=11)
-Intimate partner sharing (n=10)
-Ambivalence about using old
Equipment (n=10)
-Not considering sterility of equipment
aside from syringe (n=4)
-Knowing HIV/HCV status (n=12)

Health and healthcare
Social context
Health and healthcare

-Using proper equipment for
successful, comfortable, sterile
injection (n=6)
-Convenience in getting new supplies
(n=4)

Health and healthcare

-Wanting to avoid using other’s
medical supplies (n=4)

Social context

-Cleaning used equipment (n=10)
-Maintaining adequate stock of sterile
Supplies (n=5)
-Concern for the safety of other PWID
(n=9)
-Concern for personal safety (n=4)
-Knowing HIV/HCV status (n=12)
-Concern for public safety (n=2_

Health and healthcare
Health and healthcare

Health and healthcare
Social context

Built environment,
community context,
economic stability

Social context, health and
healthcare
Health and healthcare
Health and healthcare
Health and healthcare,
Community context
Note: Behavioral or situational concepts are actions or circumstances that influence
misuse. Motivational concepts are thoughts/feelings/desires that lead to misuse.
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Sterile supply stability emerged as a theme correlated with the likelihood of sterile
drug equipment sharing and reuse. Having high risk behaviors or attitudes surrounding
injection drug use emerged as a theme because participants may disregard infection
control measures (sterility) due to ambivalence about sharing with sexual partners, or
because PWID culture suggested that a practice may have been safe or low-risk. Having
the right equipment at the right time had a positive impact on participants’ use of sterile
injecting supplies; however, when the proper equipment was not available, reuse of used
supplies was common. Despite the high-risk nature of injection drug use, participants
valued safety from both public and personal health views.
Sterile Supply Stability
Lack of access to sterile equipment at the time of injection was a significant factor
in personal drug injecting equipment re-use, receptive syringe re-use, and sharing of used
equipment with others. Interview participants reported personal equipment reuse was
commonly practiced when sterile supplies were not immediately available. Participants
were aware of their need to return to SEP, but may have been unable to do so due to
transportation difficulties or limited SEP hours, reflective of the economic stability social
determinant (limited money for transportation) and health/healthcare (SEP is closed).
Joe finds that limiting supplies to 20 syringes more than what is returned may not
be enough for some drug injectors. In cases where Ashlee could not make it to the SEP in
time for a resupply of equipment, she notes “I’ll try to just use them once, but then things
will come up, and I won’t make it [to the SEP] by the time they close, or whatever else.
And then I’ll end up going in to my ‘just been used once’ stash in my little container.
And I’ll end up using it again. Just until I can make it here.”
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Three SEP participants reported “laziness” as an inhibiting factor in using sterile
equipment for 100% of injections. Bolivar recognized bacterial contamination of cotton
filters, but admitted he may reuse them because he is “just being lazy.” Chris explained
how he and others may not “feel like they can get up and go to the other room to get [a
syringe]. They get the same one they already used. Most of us think it’s safe, you know. I
mean, if I used it, I think it’s clean. So why can’t I reuse it again?”
Motivation to use sterile supplies fluctuates for Joe, who said, “…if I know that
I’m low, or if I’m out in the field and I don’t have the motivation to get up and go get
more, then I say, ‘Who cares?’ So, it’s just…it’s petty.” Interestingly, Joe points out a
low supply and fear of arrest (community context social determinant) contribute to the
problem of equipment reuse. “If I had more [supplies], you know, the laws would help,
too. I could carry more with me.” Joe goes on to say, “Because you can’t carry [syringes],
so I mean if they catch anything on you, then you’re in trouble. So, I don’t want to carry a
whole bunch of stuff with me. But also, if I went into a situation where I run out, then I’m
going to have to reuse.”
The majority of interview participants expressed a strong desire to preferentially
give away sterile supplies should another PWID be in need, even if it meant depleting
their personal sterile equipment stockpile. In turn, this leads SEP participants to
personally re-use their own equipment in order to provide sterile equipment to another
PWID, reflective of the social context social determinant. Some participants were willing
to share their used supplies with others when they were personally out of sterile supplies;
however, attempts to sanitize/sterilize the used equipment took place.
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Applying the SDOH model to sterile supply stability uncovered how PWID
utilizing SEP encountered a number of socio-economic factors that limited their ability to
use only sterile injecting equipment. For Joe, transportation barriers (economic stability
determinant) limited his ability to consistently access SEP. He was also hastened by fear
of arrest (community context determinant), as carrying drug paraphernalia is illegal in
Kentucky. For Ashlee, the SEP operating hours created a barrier (access to healthcare or
community context determinant). Interestingly, the preference to give away sterile
supplies to other PWID was an example of the social context determinant, and was as a
positive form of social cohesion for the recipient. For the equipment provider, however,
this social cohesion created a barrier to consistent sterile supply access because supplies
were reused, and they were not necessarily sterilized properly.
High Risk Behaviors and Attitudes
Injection drug use is already considered a high-risk behavior, but in the context of
PWID using SEP services, high risk behaviors and attitudes may occur due to low health
literacy. One such high risk behavior is the common practice of making a wash, which is
a common practice described by participants throughout the study. A wash is made from
collecting used filters such as cottons or cigarette filters, then adding water to release
leftover drug residue from the original and/or subsequent preparations. A used cooker is
sometimes kept for the same purpose. Amanda describes a wash: “I just let the drugs
build up in [the cotton]. If I come up hard one day, I throw a couple of cottons in the
water, smash them around [then inject the solution].”
Having a wash available addresses an addicted person’s urgency to use drugs by
helping them to avoid withdraw symptoms. A wash may provide enough drug to limit
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withdrawal symptoms long enough for the PWID to obtain a new supply of drugs. SEP
participants may save their cottons or cookers for their own wash at another time, or give
away their used supplies for a wash to another in need. Regardless of who might be using
a wash, there was a general lack of recognition that bacterial or viral contamination takes
place with these particular pieces of drug injecting equipment (low health literacy). Shay
said she “never even thought about [used cookers] being dirty…I was just thinking
needles, you know?” And Amanda reflected, “The cookers and things like that; I guess
I’m probably not careful with those. And I probably should be, because I forget about
them. You know, you stick a syringe in your cooker, and it’s just the same as, you know
[the syringe]. You know, and I guess I don’t think of [the cooker] that way.” Shay and
Amanda’s examples of low health literacy, part of the health social determinant, explain
why some SEP participants do not hesitate to use a wash, especially the urgency to inject
is secondary to experiencing unpleasant withdraw symptoms.
Injecting drugs with an intimate partner appears to be another common high-risk
behavior driving reuse of drug injecting equipment that was previously used by another
person. Sharing used equipment with an intimate partner was felt to be relatively safe or
easy. Kitty reported sharing used equipment from her boyfriend of 10 years: “We were
always together and I had to keep up with everything in my bag... It’s just easier to mix
all of our stuff up together, and then you know, draw it up and split it. It was just easier.”
Liz explains, “It seems different if you actually share with your boyfriend or girlfriend or
whatever, because you have been together for so long. So whatever one of you has, you
both have. That’s how I see that.” Shelby reported receiving used equipment from her
boyfriend, and explained, “A lot of the time we share stuff just because we keep all our
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stuff together, usually. So, it’s kind of hard to know whose is whose sometimes. If you
were using, which we do reuse a lot, if we end up reusing [a syringe], it’s hard to know
who has used it before. Same thing with cottons.”
Eight interview participants were against the notion of sharing their used
equipment or receiving used equipment from people outside of an intimate relationship,
suggesting their degree of health literacy was adequate enough to understand the risk of
disease transmission from person-to-person through shared equipment. However, those
with drug injecting intimate partner relationships described ambivalence about re-use and
sharing with that partner. Amanda and Kitty readily shared with their intimate partners
because it was easy or convenient, and accepted in the social context determinant. Others
still preferred to not share at all with their partners, but might do so when there were no
supplies or the injection was proving to be difficult. There was no concern for acquiring
new infectious disease as they both assumed to have the same infection, or no infection at
all. However, none of the participants appreciated the risk of developing bacterial
infection as a result of contaminated equipment when asked about it, suggesting an
element of low health literacy persists despite the social context between injecting
partners creating a sense of well-being. Participants described feeling safe when injecting
drugs with an intimate partner.
For participants who injected with non-intimate partners, it was important to
know the serostatus of the used equipment provider. Meaning, if the recipient knew about
the HIV or HCV infection status of the equipment provider, they would consider using
the non-sterile equipment. From Tim’s perspective, asking about serostatus would
determine who he may take used equipment from: “Whenever you reuse a syringe of
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somebody else, depending if you already have hep C or are…basically, if I do use from
anybody, I know at least a little bit of their background as far as their blood, from
asking.” Having the same serostatus as an injecting intimate partner was assumed, and
further contributed to ambivalence in accepting used equipment. From a SDOH
perspective, understanding serostatus is an important, positive indicator of health literacy.
The cohesion (social context determinant) between intimate partners appeared to
contribute to syringe and injection equipment misuse because a sense of convenience
(Kitty and Amanda) and safety (Ashlee) had developed. When supplies were already in
the environment, it was convenient for both parties to share. The practice was not
perceived as high-risk because participants did not appreciate the risk of negative
consequences beyond the spreading of infectious disease when sharing with their
partners, and a sense of safety was achieved. For non-intimate partners, sharing of used
equipment was avoided except when the provider’s infectious disease status was known.
This, too, is an example of social cohesion. Participants with known HIV or HCV were
unlikely to give away used equipment to others without the disease.
Having the Right Equipment
Comfort during the injection procedure emerged as a theme supporting the desire
to limit syringe and equipment misuse. Using a filter/cotton helped limit debris from the
drug preparation process from entering the body and reduced “cotton fever” for Ashlee.
Several participants suggested that using a filter helped limit dulling of a new needle,
making for a more comfortable injection. Used cottons become hard, which damages the
needle bevel. Multiple participants endorsed desire to always use a new syringe in order
to avoid discomfort while injecting. Recognition that sterile supplies help with injection
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comfort supports continued behavior of using only sterile equipment. Unfortunately,
participants reported they were likely to engage in equipment reuse if they ran out of
supplies, rather than waiting until they could visit the SEP again.
In some instances, not having the proper syringe available at the time of injection
may lead to misuse behaviors. This was particularly evident between intimate partners, as
previously described. In cases of personal reuse, Amber noted how important having the
proper syringe size was to her in determining if she would reuse one of her personally
used syringes, “…I actually had a couple of the short ones on accident, and you know, I
can’t use those.” For cookers, Kitty described how she had adapted her cookers to avoid
burns before the SEP began carrying cookers with a handle:
I finally got rid of the spoon when they impounded my car. They took my spoon,
and then I started coming here and these caps, the big ones that you guys have…So
I do heroin, and I always put heat to it to cook out as many impurities as I can
because I still don’t know what I’m sticking in my arm. But, you know, I try to be
as safe as I can. So, you know the barrettes? The snap barrettes? Like, I bought a
six pack of Hello Kitty snap barrettes and that’s how I would hold the cap to heat
it up before they started having ones with handles. I would put that little snap
barrette on it.
Having the desired or proper drug injecting equipment helped ensure comfort during
injection or the drug preparation process. Participants tried to maintain sterile stock of
their preferred equipment, but some reused old preferred equipment in the setting of nonpreferred sterile equipment if it meant for a more comfortable injection. Having the right
equipment for injection does not clearly fall within a SDOH. Rather, it speaks to the need
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for SEP to provide a variety of injecting equipment choices, and the need to provide them
in adequate quantities.
Trying to Be Safe
Unfortunately, syringe and injection equipment misuse and sharing were common
among interview participants. Participants tried to be safe by avoiding any need to share
or reuse by always having ample supplies of sterile equipment on-hand. When this was
not possible, participants continued to convey a sense of the need to be safe from multiple
perspectives. Most participants attempted to clean equipment before reuse out of concern
for personal safety and the safety of other PWID. Knowledge of one’s HIV and/or HCV
status also contributed to perceived safety when reusing or sharing supplies. Secondary
exchange practices not only helped provide sterile supplies when possible, but also
allowed SEP participants to disseminate education and best practices to non-SEP PWID.
According to interview participants, maintaining adequate sterile injecting
supplies limited their perception of the need to share or reuse equipment. However, if
supplies were depleted, whether from unexpected secondary exchange or inability to
return to the SEP, equipment reuse behavior became common. Providing people outside
of SEP with SEP supplies and education is considered secondary exchange. Bolivar says
he “will maintain a stockpile whether I'm using much or not at all, for those
acquaintances of mine. I'm omitting the exchange program” because he understands there
other PWID who do not use SEP services. Chris feels sterile SEP supplies are in demand,
“mostly everybody I know comes here. Or you know, gets them from somebody else who
does come here.” Kitty also supports secondary exchange while noting how important it
is to inject using sterile supplies:
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I break the rules of the program and it's pretty messed up. But I pick up syringes
from a lot of people who live close to where I live, and I bring them back for them
because they do not have the means to get here, and I bring things back for them.
And while that does violate the rules of the program, I... (Pause) I have been in
situations where I had no way to get syringes, or you know, the things that I needed
to safely inject... and I just don't want to let people around me be in that same
situation if I can prevent it.
Some SEP participants acquire equipment or supplies in order to trade them for drugs or
sell them for cash. This behavior creates an economy around sterile SEP supplies, which
speaks to the importance of economic stability. Billy has bartered SEP supplies for drugs:
I befriended a guy in camp, and he needed some new needles and stuff. And he
offered to give me some dope if I would come down here, and get some needle
exchanges, and leave, that for him. So, I come down here and get my little I.D. so
I can get a needle exchange, and I figured, ‘What? Why not?’ So, I sat down and
had him shoot me up the first time, and taught me how to do it myself. So, I've
been on [heroin] ever since. But he was the reason I came down here. To mainly
start picking up the needles.
Billy also said, “Well sometimes I will give them [bartering partners] new stuff still in the
bag and not ever been used yet... for, you know, if I'm running low on dope or something...
I'll trade some for a couple of shots of what dope that they got.” Chris recognized the
supply-and-demand principle: “People with the dope pretty much... like, they can pretty
much get what they want. A clean [syringe], a dirty [syringe]. They'll find one or they'll
buy it from somebody who does have one. I've seen that a lot of times. People get it from
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the [syringe] exchange [program] and sell them on the street. People who don't even use
[will sell them].”
Interview participants preferred to provide sterile equipment to others, but some
situations could increase the likelihood of a SEP participant sharing used equipment with
another PWID. For instance, when sterile equipment was not available, interview
participants described cleaning their equipment before sharing as a sentiment of
preventing injury, which is a demonstration of positive health literacy. Amanda explained
she does not “give my syringes away freely. I’m not going to. Those are mine. Those are
to protect me, and keep me safe. And, unless it’s just a desperate situation for someone
else. I do not want to give my used things away.” Ashlee was surprised when people
asked for her used equipment: “It astounds me how many people are so comfortable with
that, and they don’t even clean them. I know cleaning them with bleach or alcohol, or
whatever, doesn’t necessarily make it okay. But still, they throw caution to the wind.”
She attributes the asking behavior to younger injectors:
The girl I live with, she’s like 23. And a lot of the friends she has that are asking
for these things a lot are super young, you know, in their early 20s. And I guess
they just don’t know, just like when I was young and dumb and just careless.
They haven’t seen all this stuff yet. It hasn’t affected them. So, it doesn’t really hit
home, and I guess that stuff just comes with age. Just seeing it, and it really
sinking in.
When sharing or reuse is necessary, the majority of interview participants
described a variety of attempts at cleaning or sterilizing their equipment. Those who
personally re-used items such as filters/cottons made no attempts to clean them before the
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next use. For cookers, Tim might use an alcohol swab before use. Shay would reuse her
cooker until “it looked dirty.” In some cases, however, no cleaning procedures took
place. Joe prepared a single syringe to be used throughout the day, without regard to the
possibility of it becoming contaminated with bacteria or debris. Although most
participants reported attempts at cleaning procedures for syringes they intended to re-use
or share, they did not consider the cleanliness or sterility of other equipment.
Disappointingly, most cleaning procedures described by participants were not in
line with the Centers for Disease Control recommendations (CDC, 2018). The CDC
recommends only pure bleach with water rinses for sanitizing used syringes. Tim
reported using hand sanitizer; five participants suggested using alcohol as a rinsing agent.
Only Bolivar was able to describe a cleaning procedure close to the CDC
recommendations, which uses a series of bleach and rinse water. Interestingly,
participants describing any type of sanitizing procedure also noted that they did not
believe their methods to be effective in prevention HCV and/or HIV transmission. Ashlee
thought, “I know cleaning them with bleach or alcohol, or whatever, doesn’t necessarily
make it okay.” Shay said, “…I read that you can use alcohol and it will clean the needle,
but I don’t trust it.”
Trying to be safe was very important to Tom, who refuses to share his used
equipment with anybody, regardless of circumstance, because he has human
immunodeficiency virus (HIV). He explains, “I wouldn’t give them used ones. That’s just
something I won’t do. Just because it’s such a big deal to me. And I don’t know if I could
deal with it very easily if I knew that somebody became [HIV] positive because they used
one of my used syringes and didn’t clean it properly or something. I mean, I know that’s
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a risk they’re taking, and they’re assuming. But I would still feel responsible.” Chris, who
has hepatitis C virus infection, prefers to know the serostatus of people he may share one
of his used syringes with: “They usually got it, too. It’s not like I don’t have anything
more, but, you know, I wouldn’t just give it to someone that didn’t have it. And I hate for
people to reuse… I would give anybody [a new] one if I had it instead of selling it or
reusing it. Just for the fact of the health issues.” Tom and Chris’ regard for the safety of
other PWID because of their own infections further support the concept that PWID are
interested in the safety of others when it comes to syringe and equipment sharing
practices.
Trying to be safe demonstrated a strong sense of community among PWID. It
demonstrated elements of positive and negative health social determinants (clarifying
serostatus before sharing versus ineffective cleaning procedures for used equipment), as
well as social contexts that may lead to equipment misuse. Understanding the need to
provide sterile equipment for personal safety and the safety of other PWID was consistent
with social cohesion (community context determinant) and the desire to maintain a safe
environment through proper syringe disposal via secondary exchange (neighborhood
environment determinant). For people like Tom, trying to be safe also meant he had good
health literacy (health determinant).
Limitations
There are several limitations to this study. The study was conducted for a
specified period and this sampling strategy may have missed people who visit SEP
outside this time period. Convenience sampling allowed for subject self- selection which
may have failed to identify additional social determinants influencing drug injecting
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equipment misuse, as well as failed to capture additional motivations, situations, and
behaviors by those who did not participate in the study. This study took place in an urban
setting where the majority of subjects in both the qualitative and quantitative portions
were white. Differences were not explored between people injecting different substances,
making comparison of behaviors specific to heroin, methamphetamine, or other
substances beyond the scope of this study.
Conclusion
Syringe and drug injection equipment sharing and reuse are common among
people participating in SEP. There appears to be common SDOH that lead to personal
reuse, receptive reuse, sharing of used equipment, and sharing of sterile equipment
despite participation in SEP. The most common SDOH influencing drug injecting
equipment misuse was social context, wherein PWID see themselves as a community
sharing common needs and practices. These behaviors appear to be similar to those who
are not engaging in SEP services, including injecting with an intimate partner and having
friends who inject (Munoz et al., 2015). Health and healthcare determinants were also
identified, mainly in terms of low health literacy regarding disease transmission risk for
misusing non-syringe equipment such as filters and cookers.
Having consistent access to sterile supplies through SEP helped most participants
avoid personal and receptive reuse, as well as limited sharing of used equipment. It
helped facilitate secondary exchange or providing various pieces of sterile equipment to
others in need. When participants reported sterile supply stability was compromised, drug
injecting equipment misuse took place. The literature supports this occurs outside of
SEPs, where having limited access to sterile syringes and homelessness increases the
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likelihood of sharing used equipment (Bozinoff et al., 2017; Munoz et al., 2015). Sterile
supply stability issues brought about by fear of arrest or strong police presence may lead
to increased sharing of used equipment (Flath et al., 2017; Munoz et al., 2015).
SEPs should ensure services are easily accessible by considering neighborhood
and built environment determinants such as SEP hours, locations, and PWID safety. The
economic instability (including issues around transportation, the incompatibility of SEP
hours and typical working hours) of SEP participants should be considered. SEPs should
continue working with police to ensure the threat of arrest and incarceration among
participants is limited, and work with stakeholders to change drug paraphernalia laws.
Policies protecting participant anonymity and setting boundaries with law enforcement
are critical. It is important to consider economic stability in determining supply
distribution models as those with the least stability appear to have the most difficulty
maintaining adequate sterile supplies.
Despite the education PWID in SEP receive, high-risk behaviors and attitudes
persist around saving drugs for later use (a wash). Although the intent of using a wash is
to avoid withdrawal symptoms, PWID may experience cotton fever, a flu-like illness
resulting from contamination of used cotton filters with fungi or bacteria (Xie, Pope, &
Hunter, 2015). Such an infection may lead to hospitalization and withdrawal. There is
lack of recognition that injection equipment aside from the syringe becomes
contaminated with viruses and bacteria that pose a risk for harm. Heimer et al. (2018)
demonstrated hepatitis C virus can be transmitted in water from contaminated syringe to
a cotton filter, and from the cotton filter into a new syringe. As such, it is important for
PWID using SEP services to understand that the risk of acquiring infectious disease goes
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beyond used syringe sharing. SEPs should work to continuously improve the health
literacy of participants in an effort to avoid such health-related harms.
Other high-risk behavior centers around injecting with others, especially intimate
partners. Outside of SEP, Morris et al. (2014) noted a five times higher risk of receptive
syringe reuse among intimate partners, leading to increased incidence in infections such
as hepatitis C virus. Simmons, Rajan, and McMahon (2012) suggest that emotional and
practical influences (such as convenience) contribute to intimate partner injecting. It is
important for SEP participants to understand the risk of bacterial and viral contamination
that occurs in used drug injecting equipment. SEPs must understand the needs of
participants who inject with intimate partners may be different from those who do not.
Exploring the social contexts in which each SEP participant injects could help staff
determine which resources should be employed, and which educational components are
offered.
Future studies may look to replicate both the quantitative and qualitative findings
at SEPs in other areas, as well as consider differences in SDOH among urban and rural
PWID in SEP. Interventions can be developed to reduce the likelihood of intimate partner
sharing and reuse. Policy changes using SDOH as a framework can be implemented to
ensure PWID in SEP have access to ample sterile supplies, rather than limiting new
supply distribution based on what is returned. Secondary exchange initiatives may be
piloted, explored, and developed to help improve access to SEP services among PWID
unable or unwilling to participate in the primary program, especially those with
substantial difficulty with economic stability. Using SDOH as a framework for policy

70

development at the local level could provide meaningful changes. The SDOH may be
used for future research to further explore PWID.
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CHAPTER IV
HARM REDUCTION, SYRINGE MISUSE, AND NURSING’S CODE OF ETHICS
Executive Summary
People who inject drugs (PWID) often face shortages in their sterile injecting
equipment supply. They may use a number of strategies for acquiring sterile drug
injecting equipment, including participation in harm reduction programs such as syringe
exchange programs, engaging in pharmacy syringe sales, or purchasing sterile supplies
from a drug dealer. In light of ongoing hepatitis C virus (HCV) infection and the opioid
epidemics, harm reduction strategies that improve PWID access to sterile drug injecting
equipment are critical. This policy brief describes ways in which PWID may access their
sterile supplies, discusses the strengths and limitation of various supply acquisition
approaches, highlights the ethical importance of harm reduction-based nursing care, and
presents ideas for improving sterile supply access through nursing care. Incorporating
harm reduction concepts into nursing care will help reduce health disparities among
PWID, and may increase their ability to consistently use sterile injecting supplies with
each injection episode.
Introduction
The concept of harm reduction was developed during the 1980s in response to the
growing human immunodeficiency virus (HIV) epidemic, with rapid growth after HIV
was linked to injection drug use. Harm reduction uses a pragmatic, non-judgmental
approach to educating PWID on safer use practices, disease prevention, wound care, and
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other areas such as legal needs, housing support, employment opportunities, and more
(HRC, 2019). Table 1 displays the principles of harm reduction.
Table 1
Principles of Harm Reduction
Principle
1

Accept that drug use is part of reality, but work can be done to minimize its
effects. Drug use should not be ignored, nor condemned.

2

Understand that drug use encompasses a continuum of behaviors, from severe
abuse to complete abstinence, and that there are safer ways of using drugs.

3

Cessation of all drug use is not a criterion for measuring a successful policy or
intervention; consider individual or community quality of life as a criterion for
success.

4

Encourage a non-judgmental and non-coercive approach to providing services
(such as syringe exchange programs) in an effort to assist PWUD and their
communities to reduce drug-related harm.

5

Encourage PWUD to have a voice in the creation of programs and policies meant
to benefit them, rather than having programs and policies created for them
without input.

6

Recognize PWUD are their own primary actors in reducing harms of their own
use, and this encourages them to share information and support each other.

7

Many social inequalities affect PWUD’s vulnerability and capacity to effectively
manage drug-related harms.

8

Harm reduction does not attempt to minimize or ignore the real threats and
dangers associated with drug abuse, whether the drugs used are licit or illicit.

Note. (HRC, 2019).
Harm reduction tools include syringe exchange programs (SEP), syringe vending
machines, secondary or peer exchange, and supervised injection facilities. Each harm
reduction tool employs a basic program of supplying sterile drug injection equipment to
PWID with the expectation used supplies will be returned for proper disposal. Education
may be provided face-to-face, or in written materials. These programs have been shown
to reduce the spread of infectious diseases such as hepatitis C virus (HCV) and HIV. The
purpose of this policy brief is to explore the problem of sterile drug injection supply
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access among PWID both in and outside of SEP programs, explore policy alternatives,
and describe how nursing can ethically support such policy alternatives.
Accessing Sterile Injecting Supplies
Drug injecting supply access within SEP
Multiple models of SEP supply distribution exist, and are briefly described in
Table 2. There are variations in the types of supplies available at SEP as well, with some
offering robust selections, and others only syringes. For example, SEPs in West Virginia
and North Carolina may be limited to syringes and alcohol swabs. However, SEPs in the
neighboring state of Kentucky have a wide assortment of available supplies such as
filters, water, cookers, and alcohol swabs available (Bixler et al., 2018). Having
availability of multiple choices for each type of equipment, including different sizes
(gauge and needle length) of syringes and needs-based distribution models of SEP
programs are considered best practice (NYC DHMH, 2009). Depending on where a SEP
is accessed, participants may be able to acquire enough supplies to share with other
PWID (secondary exchange), or conversely experience limitations on sterile supply
access based on the quantity of syringes returned.
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Table 2
Syringe Exchange Program Distribution Models
Model
Program Description
One-for-one exchange
For each used syringe returned, participants may replace it
with a sterile one.
Less than one-for-one
exchange

Like one-for-one, this program requires an exchange of
used-for-new syringes, but the syringes must originate
from the SEP. For example, a syringe from a pharmacy can
be returned after use, but it will not count towards a sterile
replacement because it did not come from that particular
SEP.

One-for-one plus
exchange

Participants may exchange the number of syringes returned
and take an additional pre-determined amount in an effort
to build up a stable supply of sterile equipment between
SEP visits. For example, a participant may return 20
syringes and have 30 provided in exchange (plus 10).

Needs-based

Participants may obtain the number of sterile syringes
needed without regard to the number of syringes returned.
Participants are not limited on the frequency of their visits.
This approach is considered best practice.

Note: (Bluthenthal et al., 2007; Sherman et al., 2015).
Drug injecting supply access outside of SEP
When not participating in a SEP, PWID engage in a number of ways to secure
sterile injecting supplies. Strategies include purchasing syringes and other needed
supplies from a pharmacy, receiving supplies from a peer who is involved in SEP
(secondary or peer exchange), trading drugs for sterile supplies, obtaining sterile
equipment from their drug dealer, diverting syringes from patients with medical needs
(like a diabetic on insulin), and more (Behrends, Li, & Gibson, 2017). How PWID obtain
their sterile supplies influences their degree of syringe reuse, as described in the
following paragraphs.
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Pharmacy sales.
In the United States, 23 states have legalized prescription sales of syringes to
PWID (CDC, 2017). Figure 1 displays the distribution of states in which PWID might
obtain supplies through a pharmacy. In several states, pharmacists are required to
maintain a log of customer names, addresses, and the reported intended use of the
syringes sold (Goodin., Fallin-Bennett, Green, & Freeman, 2018). Recording of such
information is a barrier to some PWID, as anonymity is critical (Goodin et al., 2018).
However, access to syringe sales through pharmacies is an important source for sterile
supplies, and uptake of syringes from pharmacies has been seen nationwide (Zaller et al.,
2012). Importantly, some PWID purchasing syringes through pharmacies continue to
engage in high-risk injection behavior, including reuse of used syringes (Zaller et al.,
2012; Zlotorzynska, Weidle, Paz-Bailey, & Broz, 2018). In a study of young PWID, up to
49% reported reusing equipment despite access to pharmacy sales (Zaller et al., 2012).
Studies have identified barriers such as stigma and denial of sales by pharmacists (despite
legality) contribute to PWID avoidance or limiting of pharmacy syringe purchasing, but
in areas with high drug use and overdose incidence, pharmacy sales are an integral part of
harm reduction (Goodin et al., 2018; Meyerson et al., 2018).
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Figure 1. Pharmacy syringe sales are legal in much of the United States. Delaware and
Tennessee are the only states in which pharmacy syringe sales to PWID is explicitly
illegal. Twenty-two states do not have a specific policy for or against syringe sales to
PWID (CDC, 2017).
Secondary or peer exchange.
Participants in SEP obtain enough injecting supplies for themselves, but may also
collect supplies to be distributed to other PWID. This practice is known as secondary
exchange or peer exchange. Secondary exchange is common across the United States and
serves as an opportunity for SEP harm reduction principles to reach PWID who might not
directly engage in SEP services (Behrends et al., 2017). Brothers (2016) suggests there
are a number of reasons PWID may not visit SEP, including distance, operating hours,
disability, fear of police, fear of being identified, and feelings such as shame, anxiety, and
stigma. PWID attending SEP who provide sterile supplies to other PWID serve important
role in sterile supply access solutions (Behrends et al., 2017; Brothers, 2016). The SEP
participants providing secondary exchange are often friends, family members, or intimate
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partners of those receiving supplies as part of secondary exchange (Behrends et al.,
2017). Secondary exchange helps improve health equity because of its ability to reach
PWID who might not otherwise have access to sterile drug injecting supplies and harm
reduction education.
Trade and drug dealer supply sales.
Kuyper and colleagues (2006) described sterile syringe trade and sales among
PWID, noting that such supplies may be obtained from medical patients such as
diabetics, pharmacies, SEPs, or other PWID. In areas without SEP or before a SEP
opened, many PWID reportedly obtained their injecting supplies through trading drugs
for supplies, or by purchasing sterile supplies directly from their drug dealer (Kuyper et
al., 2006). In Los Angeles, where SEP and pharmacy sales are legal, up to 16% of
respondents reported obtaining their syringes from an unauthorized source (i.e. not a SEP
or pharmacy) within the past six months (Quinn, Chu, Wenger, Bluthenthal, & Kral,
2014). In Australia, syringes received through trade or dealers were typically in small
amounts (four or less) (Bryant & Hopwood, 2009). Anecdotal reports from the SEP
studied by Cave (2019) suggest trading syringes and supplies for drugs or acquiring
syringes from dealers occurs despite SEP and pharmacy coverage in the area; however,
little else is known as it has not been studied.
Policy Alternatives: Increasing Access to a Consistent Supply of Sterile Equipment
Despite the use of SEP or other means of acquiring drug injecting supplies,
significant numbers of PWID share or reuse equipment (Behrends et al., 2017; Cave,
2019; Des Jarlais et al., 2015; Flath, Tobin, King, Lee, & Latkin, 2017; Golub et al.,
2007). Reasons for sterile supply interruptions and challenges are numerous, and may

78

include difficulties with transportation (Canary et al., 2017; Cave, 2019), seasonal
changes (Allen, Ruiz, Roess, & Jones, 2015), police presence or fear of arrest (Beletsky
et al., 2014; Cave, 2019; Davis et al., 2019; Flath et al., 2017; Munoz, Burgos, CuevasMota, Teshale, & Garfein, 2015), and problems with SEP supply limits or operating
hours (Bluthenthal et al., 2007; Cave, 2019; Davis et al., 2019). It is important to
recognize there are a number of mechanisms that may help overcome such barriers,
resulting in improved sterile injecting supply stability for PWID. These mechanisms
include the use of sterile supply vending machines, utilizing mobile distribution units,
scaling up secondary or peer exchange practices, eliminating one-for-one SEP
restrictions, and increasing pharmacy coverage of sterile injecting supplies. Increased
access to a consistent supply of sterile drug injecting equipment will improve the health
of PWID.
Vending Machines
Syringe vending machines distribute sterile injecting supplies and serve as a
return receptacle for used syringes (Philbin et al., 2009). They are used worldwide and
may reduce SEP staffing costs, provide anonymity, allow 24/7 access, and may attract
PWID who otherwise would not engage in harm reduction services (Philbin et al., 2009).
Vending machines were first operational in the United States in Las Vegas, Nevada
beginning in 2017 (O’Hara, 2017). The machines provide sterile injecting equipment,
wound care kits, and safer sex kits. The machine supplies are free, but people wishing to
use them must first register with a local harm reduction program to obtain a unique code
that helps the program track machine and PWID interactions (O’Hara, 2017). During the
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first year of the Las Vegas program, machines distributed 37,000 syringes to more than
400 participants (Young, 2018).
In Europe and Australia, where syringe vending machines have been used since
1987, syringes are distributed after monetary payment or exchange of used syringes
(Islam, Wodak, & Conigrave, 2008). Like the Las Vegas machines, European and
Australian machines are stocked with healthcare items, but also have educational
pamphlets (Islam et al., 2008). They have been shown to increase access to sterile
injecting supplies, reduce incidence of used syringe sharing, increase access to health
information and health services, and demonstrated safe syringe disposal (Islam et al.,
2008; Obadia, Feroni, Perrin, Vlahov, & Moatti, 1999). The machines may lead to cost
savings, and are considered cost effective in their ability to reduce HIV and HCV
transmission among PWID, even if the equipment was provided at no charge to the
participant (Islam et al., 2008; Otiashvili, Kirtadze, Vardanashvili, Tabatadze, & Ober,
2019). Public perception of the syringe vending machines is generally positive among
Australians (White, Haber, & Day, 2016), and PWID report positive experiences with
them in the country of Georgia (Otiashvili et al., 2019). There is some evidence that
syringe vending machines reach PWID who would otherwise not access any type of harm
reduction program (Islam & Conigrave, 2007). Currently, there is no literature describing
perceptions/attitudes towards syringe vending machines among United States PWID or
stakeholders. To-date, Las Vegas remains the only location in the United States utilizing
this harm reduction strategy.
Mobile Units
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SEP participants report location and transportation difficulties as reasons for not
regularly attending. Strike and Miskovic (2018) conducted a literature review and
provided a detailed description of mobile units providing SEP services, where traditional
SEP services have been provided in brick and mortar, fixed locations. They included
literature from the United States, Canada, and Russia to describe how mobile SEP units
typically operate in a van or bus. Services provided by mobile units nearly mirrored fixed
SEP services, although physical space may have been a reason for limiting some services
such as HIV/HCV testing. Mobile units have the advantage of home delivery for disabled
participants; they can quickly adapt their routes and service locations based on PWID
demand or changes in police presence (Islam & Conigrave, 2007; Strike & Miskovic,
2018). Limitations for mobile unit services include limited hours at a specific location
may result in PWID missing services until the next scheduled stop in that location (Strike
& Miskovic, 2018). This sentiment was reflected in work by this investigator (2019),
where interview participants acknowledged past inconsistent interaction with mobile
units due to limited service hours despite its convenient location. Nonetheless, mobile
units are an effective way to improve sterile supply access and harm reduction service
equity to PWID who might otherwise not engage in care (Islam & Conigrave, 2007).
Support Secondary Exchange
At SEPs without quantity restrictions, like those in California, Europe, and
Australia, secondary or peer exchange services are encouraged and recognized as a
means to reaching PWID who would otherwise have limited access to sterile supplies
(Newland, Newman, & Treloar, 2016). In California, 75-89% of SEP clients engage in
secondary exchange, and 89% of SEPs in the United States as of 2007 supported the
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activity (Behrends et al., 2017). In Baltimore, Maryland, nearly 65% of program syringes
were distributed through secondary exchange (Behrends et al., 2017). The practice
addresses SEP barriers such as limited operating hours, transportation difficulties, fear of
police, protection of anonymity, and physical disability (Behrends et al., 2017; Brothers,
2016). Benefits of secondary exchange do not exclusively address access to sterile
supplies as many PWID serving as the peer exchanger also provide harm reduction
education, information about overdose prevention, and assisting in referrals to medical
and substance use treatment (Behrends et al., 2017). PWID reached by secondary
exchangers include friends, family, intimate partners, and injecting drug customers
(Brothers, 2016). Secondary exchange was reported by 56.8% (n=63) of SEP participants
in a study by this investigator (2019), suggesting SEPs do not need to formally support
secondary exchange in order for the behavior to occur.
Although access to information and sterile supplies for non-SEP receivers of
supplies is increased, secondary exchange has notable limitations. Evidence suggests
those receiving supplies are still likely to reuse syringes and may choose to use
equipment previously used by other people (Behrends et al., 2017). Not all secondary
exchangers provide their equipment at no-cost to recipients (Brothers, 2016), which
creates a potential barrier for some to acquire adequate sterile supplies due to economic
instability. Trust is an important factor in willingness to receive supplies from others, so
the potential reach of PWID suppling secondary exchange is limited to their individual
networks (Bryant & Hopwood, 2009). Nonetheless, secondary exchange fills a critical
void for many PWID to obtain sterile injecting supplies.
Elimination of One-for-One and Less than One-for-One Exchange
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One-for-one and less than one-for-one syringe exchange models are not best
practice for harm reduction, and may lead to increased syringe and drug equipment reuse
and sharing, as previously discussed. Existing SEPs that currently operate under these
restrictive exchange models may find evidence-based practice a useful tool in changing
policy to a needs-based model. Baltimore, Maryland is an excellent example of the
impact moving from a less restrictive exchange policy (one-for-one) to the most
restrictive policy (less than one-for-one), then back again (Sherman et al., 2015). During
the time of most restriction, the SEP saw fewer new clients, and distributed and collected
about half the number of syringes they had during the one-for-one exchange period
(Sherman et al., 2015). During the most restrictive policy period, syringes were in
circulation longer with the highest chances of being reused, resulting in public health
concern for increased spread of infectious disease and other harms (Sherman et al., 2015).
Conversely, less restrictive syringe dispensing policies have demonstrated reduced
likelihood of syringe reuse and sharing (Bluthenthal et al., 2004; Kral, Anderson, Flynn,
& Bluthenthal, 2004).
Improving Pharmacy Coverage
States and locales with legal access to syringes and injecting supplies at
pharmacies have shown greater uptake of such services by PWID when compared to
areas requiring a prescription to purchase syringes (Siddiqui et al., 2015). Pharmacies
serve as an important source for PWID to obtain sterile injecting supplies, especially
when SEP services are not legal (Meyerson et al., 2018; Siddiqui et al., 2015). Studies
have also shown that the ability to purchase syringes without a prescription is associated
with less syringe sharing among PWID (Sherman et al., 2015; Siddiqui et al., 2015).
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Pharmacists have the potential to serve as harm reduction ambassadors in not only
supplying sterile injection equipment, but also providing naloxone and overdose
prevention education, HIV and HCV testing, and linkage-to-care for medical concerns
including vaccinations (Rose, Lutnick, & Kral, 2014). In Kentucky, pharmacists have
shown willingness to engage in harm reduction and syringe exchanges services, although
community pharmacists favor the role more so than those from chain stores, which may
lead to inequality among pharmacies (Goodin et al., 2018). Pharmacies serve as a critical
access point for some PWID in terms of accessing sterile supplies, but more work is
needed to ensure PWID are able to successfully complete a purchase and are not
subjected to dissuasion, stigma, or discrimination by pharmacy staff (Chiarello, 2016;
Goodin et al., 2018; Meyerson et al., 2018).
Case Study
The Commonwealth of Kentucky is facing dual epidemics: the spread of hepatitis
C virus (HCV) infection, and the opioid epidemic. Syringe exchange programs were
legalized in the state in 2015 in an effort to curtail the spread of infectious diseases
among people who inject drugs (PWID), among other goals. There are now 69 approved
SEP sites throughout the commonwealth. Even as these resources were made available,
reports were made that SEP-supplied drug injecting equipment was being shared or
reused among some SEP participants. Cave (2019) examined the frequency of, and
factors associated with, drug injection equipment reuse and sharing using cross-sectional
surveys (n=111) and estimated greater than 70% (n=78) of program participants
personally reused equipment, regardless age and gender.. Cave (2019) also identified that
more than 37% (n=42) of SEP participants received used injecting equipment from
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others. Sharing of new equipment (secondary exchange) was common (56.8%, n=63),
while sharing of used equipment was less-so (30.7%, n=34). In order to understand what
influenced SEP participant’s equipment sharing and reuse behaviors, a qualitative study
was conducted. Cave (2019) identified that unstable access to sterile injecting equipment
supplies was a fundamental reason for SEP participants’ sharing and reuse of equipment,
while the sharing of new equipment was done in the interest of keeping other PWID safe.
Multidimensional factors that are best reflected by the social determinants of
health (SDOH) model influenced subject’s ability to access sterile supplies at the SEP.
Cave discovered the economic stability determinant impacted consistent, predictable
transportation to the SEP, as well as the health/healthcare social determinant. Subjects
with limited funds for bus or rideshare fares or fuel reported inconsistent time intervals
between SEP visits that might leave them without any sterile supplies due to a longer
than anticipated visit interval. Although many subjects understood one of the many
benefits of SEP participation is a reduced risk of acquiring HIV or HCV infection, low
health literacy contributed to unsafe syringe and other drug injecting equipment sharing
and reuse practices, especially among intimate partners. The social/ community context
health determinant kept some participants from routinely accessing SEP due to fear of
loss of anonymity and arrest.
Using a policy alternative such as eliminating restrictive SEP distribution models
could help overcome these barriers by ensuring participants can acquire adequate or more
than adequate sterile supplies, including supplies for secondary exchange purposes.
Having adequate supplies allows participants to have flexibility in visit frequency and
may reduce transportation hardships by increasing visit intervals. Furthermore, improving
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access to sterile injecting supplies through bolstering pharmacy syringe sales and harm
reduction education by pharmacists could improve sterile supply acquisition through
location convenience and expanded operating hours.
Nurses have the opportunity to support PWID in accessing sterile injection
supplies. They can advocate for less restrictive SEP distribution policies and increased
pharmacy syringe sales at the local level. Nurses can address SDOH when PWID present
as patients by assessing health determinants, recognizing potential barriers to sterile
supply acquisition, then advocating for alternatives and solutions, or supplying pragmatic
education and strategies for overcoming barriers. Nurses are needed to support and
advocate for harm reduction, especially access to sterile drug injecting supplies, which is
supported by the American Nurses Association Code of Ethics.
Harm Reduction and Nursing Ethics
Canadian nurses have considered harm reduction in the context of the Canadian
Nurses Association Code of Ethics, but application of the concept to the American
Nurses Association Code of Ethics has not been described. In 2007, Pauly and colleagues
described harm reduction and its alignment with the ethical standards for Canadian nurses
across the principles of health and well-being, dignity, choice, and justice. The authors
encouraged nurses to recognize how some drug policies adversely affect patient health
and advocate for equitable change. They contend that criminalization of drug use has
created unjust circumstances and environments for people who use drugs leading to poor
health and negative social outcomes, and that nurses can empower patients by providing
evidence-based information to improve safety. They also contend that all nurses should
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insist on harm reduction strategies for individuals in all settings as they are in line with
the code of ethics.
The American Nurses Association (ANA) has published the Code of Ethics for
Nurses with Interpretive Statements since 1950, and it has been through numerous
revisions since that time (ANA, 2015). Like the Canadian code of ethics, the American
code uses principles of well-being, dignity, choice and justice within several of the code’s
provisions. In Table 3, this author identified pertinent ethical provisions in the 2015
version of the Code and their application to people who use drugs, then paired them with
related harm reduction principles. Examples of nursing care situations are described
showing the relatedness between the Code of Ethics and harm reduction principles.
Although the ANA has not specifically applied harm reduction to the code of
ethics directly, they have described the role of nurses in the ongoing opioid epidemic in
the United States (ANA, 2018). The ANA (2018) has recognized nurses are face-to-face
with PWUD, and encourage nurses to provide pragmatic, harm-reduction based
interventions and education to such people. Furthermore, the ANA (2018) supports nurse
practitioners in prescribing medication assisted therapy, opioid prescribing training to
prevent/recognize use behavior that may lead to patient addiction, learning to recognize
patients at-risk for overdose death and providing naloxone prescriptions and naloxone
training, and encourages work leading to safe disposal of unused medications. All of
these ANA-encouraged approaches are consistent with harm reduction strategies and lead
to improved health outcomes for PWUD.
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Table 3
ANA Code of Ethics Relationship to Harm Reduction Principles and Ethical Nursing Care for People Who Use Drugs
Provision (ANA, 2015)
Application to PWUD
Relevant Harm Reduction
Ethical Nursing Application to the
(Including PWID)
Principles (HRC, 2019)
Care of PWUD (Including PWID)
One: “The nurse
practices with
compassion and respect
for the inherent dignity,
worth, and unique
attributes of every
person.”

Many nurses and healthcare
professions have negative
views of PWUD which
leads to stigmatizing
behaviors against such
patients, and is a major
barrier to accessing safe,
quality, equitable healthcare
for patients (Mundy, 2012).

Recognize that drug use takes
place and that it should not be
ignored or condemned, but
faced with pragmatic strategies
that reduce harms.
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Cessation of drug use is not the
standard for measuring success;
improvements in quality of life
and well-being are markers for
showing such success.
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Nurses have a duty to avoid
stigmatizing behavior that leads to
reduced patient dignity, lack of
respect, and increased patient harm.
Providing education on how to access
sterile injecting supplies through SEP,
vending machines, secondary
exchange, pharmacy sales, etc. is
consistent with this provision.
Providing such information in a
dignified, respectful manner may lead
to reduced harm.

Table 3 (continued).
Provision (ANA, 2015)

Relevant Harm Reduction
Principle(s) (HRC, 2019)

Three: “The nurse
promotes, advocates for,
and protects the rights,
health, and safety of the
patient.”

SDOH may influence
PWUD health literacy and
ability to access healthcare,
leading to unsafe injection
practices, overdose, and
other harms.

Drug use encompasses a
continuum of behaviors, and
there are safer ways of using
drugs.

Four: Discusses the role
of the nurse in acting
“consistent with the
obligation to promote
health and provide
optimal care.”

Ensuring PWUD are
educated on harm reduction
strategies effectively
promotes health through
reducing the risk of drugrelated harm while building
a quality patient-nurse
relationship leading to
optimal care.

Social inequalities, such as
access to healthcare and health
literacy, impact PWUD’s
vulnerability and capacity to
effectively manage drug-related
harms.
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Application to PWUD
(Including PWID)

Ethical Nursing Application to the
Care of PWUD (Including PWID)

Nurses are the primary educators in
many healthcare settings, and are very
well-equipped to provide PWUD with
pragmatic education and approaches
to improve drug injection technique,
Focus on the health and safety
review the risk of harm with various
of patients through strategies
routes of administration (inhaled via
that reduce negative health
smoking or intranasal use versus
consequences through safer use. injection or rectal administration), and
strategies for infection prevention to
reduce the incidence of skin and soft
tissue infections, endocarditis, sepsis,
and infectious diseases such as HIV
and HCV. Nurses may further
advocate for patient safety through
overdose prevention education and
ensuring access to naloxone for opioid
users.
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Building trust is a fundamental
nursing skill; nurses have the ability to
build trust with PWUD. Nurses may
provide health promotion and optimal
care by ensuring PWID understand
drug-related harms and disease
prevention.

Table 3 (continued).
Provision (ANA, 2015)

Application to PWUD
(Including PWID)

Relevant Harm Reduction
Principles (HRC, 2019)

Ethical Nursing Application to the
Care of PWUD (Including PWID)

Health disparities are
abundant for PWUD, where
many have medical comorbidities in addition to
addiction or mental health
problems (Grebely, Dore,
Morin, Rockstroh, & Klein,
2017). Many PWUD are
socioeconomically
disadvantaged, have high
frequency of mental health
problems, encounter high
rates of homelessness, and
suffer from stigma (Grebely
et al., 2017; Pauly, 2008).

Social inequalities, such as
access to healthcare and health
literacy, impact PWUD’s
vulnerability and capacity to
effectively manage drug-related
harms.

Nurses should feel empowered to
address health disparities, especially in
collaboration with health allies. SEP
services are provided by a
combination of mental health
specialists and social workers; nurses
have the ability to navigate referral
systems for social support, mental
health support, and other healthcare
needs such as reproduction, infectious
disease services, and dental care.
There are natural relationships
between nurses and other healthcare
providers; nurses should leverage
these relationships to benefit PWID.

For PWUD, social justice is Encourage PWUD to have a
difficult to come by. Pauly
voice in the creation of
(2008) argues that for
programs and policies meant to
PWUD and harm reduction benefit them, rather than having
principles to reach social
programs and policies created
justice, PWUD, harm
for them without input.
reduction providers, and
nurses all need to come
together to ensure policies
are beneficial.
Note: PWUD=people who use drugs; PWID= people who inject drugs

Nurses are ethically obligated to
ensure all patients have the
opportunity to receive equal care, and
ensure effective policies are in place
that assure social justice. To help
ensure social justice, PWUD should
be included in program and policy
development. Such work will increase
equity of care and maintain the
integrity of the nursing profession.

Eight: Nurses should
collaborate with other
health professionals
leading to reduced health
disparities
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Nine: Nurses “must
articulate nursing values,
maintain the integrity of
the profession, and
integrate principles of
social justice into nursing
and health policy.”
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Discussion
Some limitations should be considered in relation to this discussion. SEPs, nonprescription syringe sales, and other harm reduction policies vary substantially from
state-to-state, and often from locale to locale. Such diverse approaches to the problem of
ensuring PWID have consistent access to sterile injecting supplies limits the ability of
this author to locate all relevant exemplars and policies. Several articles presented were
qualitative in nature and may not fully represent the magnitude of effects on sterile
injecting supply acquisition or PWID behavior. Critical data specific to Kentucky’s
PWID was not available in regard to uptake of pharmacy syringe sales and degree of SEP
participation in rural settings.
Policy Recommendations
To prevent the spread of HIV, HCV, and other infectious disease as well as
mitigate potential harms associated with injecting drugs with unsterile, used equipment, it
is critical for PWID to have consistent access to sterile drug injecting equipment. A
number of strategies to obtain sterile equipment have been employed across the United
States for decades, with needs-based models of syringe exchange programs
demonstrating the ability to consistently reduce drug-related infection and harm. PWID
can benefit from ensuring consistent access to sterile injecting supplies, especially
syringes, through reduced restrictions on SEP distribution models and formal support for
secondary exchange. Nurses should be educated on local syringe supply access and
acquisition strategies in order to provide needed information to PWID in their care, and
recognize the ethical obligation to do so.
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Given the high risk of acquiring HIV or HCV through injection drug use, it is
especially important to consider best practices in harm reduction and syringe exchange
services. Any SEP services are preferred over no services, but one-for-one or less than
one-for-one exchanges do not have the public health benefits that less restrictive policies
demonstrate. As community stakeholders, nurses should advocate for existing SEPs to
adopt the least restrictive syringe exchange policy as it should reduce the time and
number of used syringes in circulation. Nurses working with their community will
recognize the needs of PWID vary, but support for SEP services helps permit secondary
exchange practices for otherwise unreachable populations, and is in line with CDC
recommendations (Abdul-Quader et al., 2013; Behrends et al., 2017; Davis et al., 2019).
The PWID participating in this investigator’s (2019) study were supportive of the onefor-one plus model used in their SEP, but acknowledged they often ran out of sterile
supplies due to barriers reflected by SDOH leading to unexpected secondary exchange,
difficulty with SEP hours or transportation, and more. A needs-based syringe exchange
approach is best practice (NYC DHMH, 2009), and ensures that PWID have consistent
access to sterile injecting equipment. Nurses can work alongside PWID at the local level
to help overcome challenges to sterile injecting supply acquisition.
Reducing restrictions among SEP distribution models may build upon existing
programs and relationships, and may reduce public health costs through increased
prevention of infectious disease. Certainly, moving to a needs-based syringe exchange
model could help the problem of sterile supply access for the participants in this
investigator’s (2019) study because it may lead to: 1) fewer SEP visits resulting in
reduced transportation difficulties; 2) consistent sterile supply availability for those
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engaging in secondary exchange, whether planned or unplanned; 3) recognition that
PWID experience inconsistent motivation to use only sterile equipment, and that
procrastination plays a role in not returning at regular intervals; and 4) reduced demand
on SEP participants time in relation to the need for frequent visits. Future policy changes
may wish to consider sterile supply distribution via vending machines and improved
implementation of non-prescription syringe sales at pharmacies.
Nurses should recognize that harm reduction approaches are generally wellreceived by PWUD, but access to harm reduction services may be limited (Davis et al.,
2019). A number of resources to assist nurses with incorporating harm reduction
strategies into clinical care are available (ANA, 2018; Drug Policy Alliance, 2019; HRC,
2019). Without solid understanding and use of harm reduction strategies, it will be
difficult for American nurses to fully support PWUD in the context of continued health
disparities. Nurses should use ethical guidance as a means to reflect on their approach to
the care of PWUD and recognize that harm reduction principles pair well with the ANA
Code of Ethics (2015). In time, nurses should feel comfortable recommending harm
reduction strategies to PWUD as part of routine patient care, including information about
syringe exchange programs, secondary exchange, pharmacy syringe sales, and more.
Such evidence-based, cost-effective, and ethical strategies help to ameliorate the harms
faced by PWUD (Bartlett et al., 2013; Drucker et al., 2016; Nguyen et al., 2014). Without
harm reduction in patient care, PWUD may not receive the full spectrum of pragmatic
education required to reduce the spread of infectious disease, reduce the risk of
endocarditis or skin and soft tissue infections, and other health-related harms. Harm
reduction is equitable healthcare.
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Future work using harm reduction strategies and principles should begin with
implementation of healthcare policies and approaches for nurses caring for PWUD. Both
nurses and PWUD should be part of policy development, and they should aim to ensure
nurses are competent in the care of PWUD, the nature of the nurse-patient relationship is
free from stigma, and that community harm reduction services are accessible. Emphasis
on improving access to sterile drug injecting supplies should be paramount, as this is a
key issue in PWID syringe reuse and sharing behavior. Nurses should increase their
awareness of harm reduction by incorporating the concept into nursing curricula and
continuing education. Recall that development of trust is critical for PWUD engaging in
harm reduction: nurses may develop and validate tools measuring nursing attitudes and
beliefs towards various aspects of harm reduction and adapt education and policies
accordingly. Educational programs that improve nurse-PWUD relationships within a
harm reduction framework, supported by the SDOH model, may improve the quality and
equity of care PWUD receive. Future work should also explore areas in which harm
reduction is failing, and find ways to determine the root cause for its failure.
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CHAPTER V
CONCLUSION
People who inject drugs (PWID) face many problems in trying to acquire a
consistent supply of sterile drug injecting equipment. The principles of harm reduction
are meant to provide guidance on ways to protect this vulnerable group from social, legal,
and health-related harms. Harm reduction focused on prevention of negative health
outcomes may be practiced in many settings—from healthcare provider offices and
hospitals, to syringe exchange programs (SEPs), to supervised injection facilities, and
more. Chapter II outlined harm reduction in detail, and provided some evidence that
PWID generally have positive perceptions of harm reduction. Best practice guidelines for
syringe exchange programs use the harm reduction principles to support PWID engaging
in such services. Not all models of SEPs fulfill the recommend best practices, which may
lead to failure to fulfill all potential benefits of harm reduction. The social determinants
of health (SDOH) model is a useful tool and has been used to study PWID. In nursing,
SDOH has been used in quality improvement to better engage PWID in care
coordination.
Chapter III utilized the SDOH model as a conceptual underpinning for the study
aimed at estimating the prevalence of syringe and injecting equipment sharing and reuse
among PWID participating in a SEP. The urban SEP used a one-for-one plus exchange
model, and had received reports that participants were not using sterile drug injecting
equipment for 100% of their injecting episodes. The author found rates of
95

personal syringe reuse, reuse of equipment previously used by others, and rates of sharing
used equipment were common. The SDOH contributed to subject’s inconsistent access to
a stable sterile drug injecting supply, even when SEP participants were aware of some of
the harms associated with reuse of drug injecting equipment. Subjects were clear that
they valued personal and public safety despite the harms associated with injection drug
use, but SDOH could supersede their ability to maintain consistent harm reduction
practices (such as injecting with someone of the same serostatus when sterile supplies are
not available due to supply access difficulty). Future work should aim to discover
interventions to limit sharing of equipment between intimate partners, examining the
impact of implementing full support of secondary exchange and a needs-based
distribution model, and identifying ways to overcome SDOH barriers such as limited
transportation limited PWID understanding of or engagement in health and healthcare.
The policy brief presented in Chapter IV highlights some of the difficulties PWID
have in accessing a consistent source of sterile drug injecting equipment. It reviewed
methods of supply acquisition for PWID who are both involved and not involved in
SEPs. Opportunities exist to bolster sterile supply access to PWID outside of SEP
through supply vending machines, increased pharmacy supply sales and harm reduction
support, and supporting secondary syringe exchange among PWID peers. Moving to a
needs-based supply distribution model within SEPs could have a significant impact on
PWID who are adversely affected by SDOH. The concept of harm reduction is important
not only for PWID, but for those caring for this population. The nursing code of ethics is
in line with harm reduction principles; nurses should feel empowered to help PWID
overcome SDOH and/or sterile injecting supply access issues.
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Implications for this body of work include recognition that PWID are faced with
many challenges in achieving full use of harm reduction practices. Nurses have the
opportunity and ethical obligation to provide harm reduction education and care
coordination and assistance in helping PWID access sterile drug injecting equipment.
Models of SEP sterile supply distribution that limit PWID access to all of the needed
supplies is problematic, especially for PWID who face disadvantages from a SDOH
perspective. Additionally, a needs-based distribution of drug injecting supplies and
increased harm reduction principle implementation across all healthcare settings should
be implemented as it has been shown to improve health outcomes and is ethical practice.
Overall limitations include the possibility that all related publications were not
discovered due to the search strategy used and multiple synonyms across search terms.
Time constraints made it difficult to explore alternative literature resources such as gray
literature, editorials, and work published outside of journals. Research participants were
self-selected, and limited reports were available to compare/contrast findings.
Future directions for research may use the SDOH model as a tool to identify
issues and improve access to harm reduction services. Common SDOH barriers should be
addressed with policy change recommendations. A replication study among PWID in a
rural SEP should be considered in order to compare drug injecting equipment misuse
prevalence estimates to those in this urban sample, and to qualitatively examine potential
differences in behaviors and barriers among rural PWID. Future policy work should aim
to improve access to sterile drug injecting equipment through any of the means presented,
but also consider new avenues of supply delivery.
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APPENDIX C: INTERVIEW GUIDE

Examining Syringe and Drug Injection Equipment Sharing and Re-use Among
People Who Inject Drugs Participating in a Syringe Exchange Program
Interview Guide
Introduction: I have invited you here today to participate in research that will help me and
others to understand the behaviors of individuals who participate in a syringe exchange
program re-use personal equipment, use other’s equipment, or share used injection
equipment with others. This session will last 45-60 minutes and will be audio recorded to
ensure we capture what you think is important. Neither you nor your comments will be
identified.
Domains
Study Aim 3
Procurement
How one obtains sterile
syringes, water, cookers,
cotton, and other needed
equipment to perform sterile
injection

Primary Questions
Tell me about your
experiences in
obtaining sterile
injecting equipment.

Personal re-use
What might cause you
Using a personally used
to re-use your own
syringe or pieces of injection syringe/ equipment?
equipment again. Items have
not been shared with anyone.

Receptive re-use
Being the recipient of a
syringe/injection equipment
previously used by another
person, regardless of the age
of equipment, number of
uses, or cleaning procedures

Tell me about a time
you used equipment
previously used by
another person.
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Probes/ Secondary Questions
(if needed)
What is easy/difficult about
continuing to use only sterile
equipment?
What might help you or people
you know who inject drugs stop
reusing or sharing their used
syringes and equipment?
What prompts you to re-use
your own equipment?
What happens when you decide
to use only sterile equipment?
What factors might keep you
from using a sterile
syringe/equipment 100% of the
time?
What motivated you to do this?
What was going on at the time?
Tell me what might be done
through the syringe exchange
program or other program to

APPENDIX D: SURVEY
Please take a moment to complete this short, confidential survey. The results will help us improve our services for
you and others who use the syringe exchange program.
Your ability to participate in the syringe exchange will not be affected in any way by your answers or your decision
on whether or not to complete this survey.
1. What is your age (in years)?

________________________

3. Which of the following best describes you? Check
all that apply.
 White, non-Hispanic
 Black, non-Hispanic
 Hispanic/Latino/Latina
 Other (please specify)
____________________

2. Are you…?
 Male
 Female
 Transgender – ID Female
 Transgender – ID Male
 I self-identify as __________________
4. How often do you visit a syringe exchange program?
 This is my first time
 Less than once per month (Less than monthly)
 1-3 times most months (monthly or almost
monthly)
 1-4 times most weeks (weekly or almost
weekly)
 5-7 times most weeks (daily or almost daily)

5. How often do you share your used syringes,
cookers, cotton, water, or any items used to prepare
your injection with other people? (You used these
items first, then shared them.)
 Never
 Less than once per month (less than
monthly)
 1-3 times most months (monthly or almost
monthly)
 1-4 times most weeks (weekly or almost
weekly)
 5-7 times most weeks (daily or almost daily)

6. How often do you share NEW syringes, cookers,
cotton, water, or any items used to prepare your
injection with other people? (Do you share extra,
unused equipment, or pick up extra equipment to give
to people who did not go to the syringe exchange?)
 Never
 Less than once per month (less than monthly)
 1-3 times most months (monthly or almost
monthly)
 1-4 times most weeks (weekly or almost
weekly)
 5-7 times most weeks (daily or almost daily)

7. How often do you use syringes, cookers, cotton,
water, or any items used to prepare your injection
previously used by other people? (These items were
used and given to you after they had been used.)
 Never
 Less than once per month (less than
monthly)
 1-3 times most months (monthly or almost
monthly)
 1-4 times most weeks (weekly or almost
weekly)
 5-7 times most weeks (daily or almost daily)

8. How often do you re-use your own syringes,
cookers, cotton, water, or any items used to prepare
your injection?
 Never
 Less than once per month (Less than monthly)
 1-3 times most months (monthly or almost
monthly)
 1-4 times most weeks (weekly or almost
weekly)
 5-7 times most weeks (daily or almost daily)
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APPENDIX E: PREAMBLE
Examining Syringe and Drug Injection Equipment Sharing and Re-use Among People
Participating in a Syringe Exchange Program
Date: ____________
This study is about learning how often people who inject drugs who are participating in a syringe
exchange program share or re-use their injection equipment with others, and it has been approved
by the University of Louisville Institutional Review Board. You are being invited to participate in
this research study by providing the information on the attached survey. The survey will take
approximately 3 minutes time to complete.
Information provided by you will be added to the information provided by others. It will be
mathematically analyzed to estimate the rates of syringe and injection equipment sharing and reuse. The information collected may not benefit you directly. The information learned in this study
may be helpful to others.
Taking part in this study is voluntary. The Health Insurance Portability and Accountability

Act of 1996 (HIPAA) provides federal safeguards for your protected health information
(PHI). State and federal privacy laws also may also require your health information to be
protected. By taking part in this survey, you provide your permission, called your
“authorization,” for the use and disclosure of PHI. If you participate, the research team
working on this study may use and share your health information to answer the research
questions described in this document, and to make sure that the research was done
correctly. This includes things learned from the procedures described in this consent form.
Your health information may be shared with a public health authority that is authorized by
law to collect or receive such information for the purpose of preventing or controlling
disease, injury, or disability, and conducting public health surveillance, investigations or
interventions. The time period when information can be used or shared ends when all
activities related to this study are completed. By answering survey questions, you agree to
take part in this research study. You do not have to answer any questions that make you
uncomfortable. You may choose not to take part at all. If you decide to be in this study you may
stop taking part at any time. If you decide not to be in this study or if you stop taking part at any
time, you will not lose any benefits for which you may qualify.
There are no significant research-related risks, but you may experience psychological discomfort
(feelings of guilt, shame, embarrassment). The survey does not contain any information that

will identify you, and the Louisville Metro Department of Public Health will not know of
your survey participation in this study.
Individuals from the University of Louisville, the Louisville Metro Department of Public Heath,
the Institutional Review Board (IRB), the Human Subjects Protection Program Office (HSPPO),
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and other regulatory agencies may inspect the survey records. In all other respects, however, the
data will be held in confidence to the extent permitted by law. Should the data be published, your
identity will not be disclosed.
If you have any questions, concerns, or complaints about the research study, please contact:
Barbra Cave at 502-852-2010
If you have any questions about your rights as a research subject, you may call the Human Subjects
Protection Program Office at (502) 852-5188. You can discuss any questions about your rights as
a research subject, in private, with a member of the Institutional Review Board (IRB). You may
also call this number if you have other questions about the research, and you cannot reach the study
doctor, or want to talk to someone else. The IRB is an independent committee made up of people
from the University community, staff of the institutions, as well as people from the community not
connected with these institutions. The IRB has reviewed this research study.
If you have concerns or complaints about the research or research staff and you do not wish to give
your name, you may call 1-877-852-1167. This is a 24-hour hot line answered by people who do
not work at University of Louisville.
Thank you,

Barbra Cave, APRN, Vicki Hines-Martin, PhD, RN, FAAN, M. Celeste Shawler, PhD, Rachel
Vickers Smith, PhD, MPH, and Laura Smart, MD
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APPENDIX F: INFORMED CONSENT
Subject Informed Consent Document
EXAMINING SYRINGE AND DRUG INJECTION EQUIPMENT MISUSE
AMONG PEOPLE WHO INJECT DRUGS PARTICIPATING IN A SYRINGE
EXCHANGE PROGRAM

Investigators name & address:

Vicki Hines-Martin, PhD, RN, FAAN
School of Nursing
University of Louisville
4055 K Building
555 S. Floyd St.
Louisville, KY 40202
Barbra Cave, MSN, APRN, FNP-BC, PhDc
Clinical Trials Unit
University of Louisville
401 E. Chestnut St. Suite 460
Louisville, KY 40202
M. Celeste Shawler, PhD, PMHCNS-BC
School of Nursing
University of Louisville
4038 K Building
555 S. Floyd St.
Louisville, KY 40202
Rachel Vickers Smith, PhD, MPH
School of Nursing
University of Louisville
4058 K Building
555 S. Floyd St.
Louisville, KY 40202
Laura Smart, MD
School of Medicine Division of Gastroenterology,
Hepatology & Nutrition
University of Louisville
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550 S. Jackson St.
Third Floor
Louisville, KY 40202
Study sponsor: University of Louisville School of Nursing
Site where the study is to be conducted: Louisville Metro Department of Public Health
and Wellness, 400 E. Gray St. Louisville, KY 40202
Phone number for subjects to call with questions: 502-852-2010
Introduction and Background Information
You are invited to participate in a research study. The study is being conducted by Dr.
Vicki Hines-Martin, Barbra Cave, Dr. Celeste Shawler, Dr. Rachel Vickers Smith, and
Dr. Laura Smart. The study is sponsored by the University of Louisville School of
Nursing. The study will take place at the Louisville Metro Department of Public Health
and Wellness, 400 E. Gray St., Louisville, Kentucky. Approximately 20 subjects will be
invited to participate.
Purpose
The purpose of this study is to explore the motivations and behaviors of people who
inject drugs using a syringe exchange program who share or re-use syringes and drug
injection equipment.
Procedures
In this study you will be interviewed in a private session expected to last 45-60 minutes.
The interview will take place in a private room in the Louisville Metro Department of
Public Health and Wellness. The interview will be led by one of the members of the
study team. The interviewer will ask you to share through thoughts and experiences about
syringe and injection drug equipment sharing and re-use while participating in a syringe
exchange program. The interviewer is a member of the study team and will use an
interview guide to begin and guide the discussion. You do not have to answer any
questions that make you uncomfortable. The interview will be audio recorded to make
sure that all points identified in the interview are accurate. The entire study will last about
six months.
Potential Risks
There are no foreseeable risks other than possible breach of confidentiality, legal
problems, and discomfort in answering personal questions. There may also be
unforeseen risks.
Benefits
The information collected may not benefit you directly. The information learned in this
study may be helpful to others.
Compensation
No compensation is available for your participation in this study.
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HIPAA Research Authorization
The Health Insurance Portability and Accountability Act of 1996 (HIPAA) provides
federal safeguards for your protected health information (PHI). State and federal privacy
laws also may also require your health information to be protected. By signing this form,
you provide your permission, called your “authorization,” for the use and disclosure of
PHI.
If you sign this form, the research team working on this study will use and share your
health information to answer the research questions described in this document, and to
make sure that the research was done correctly. This includes things learned from the
procedures described in this consent form. They may also collect other information
including your name, address, date of birth, medical history, and other information from
your medical records from this institution and other institutions involved with this
research, as well as from your other healthcare providers (which may include information
about HIV status, drug, alcohol or STD treatment, genetic test results, or mental health
treatment). Those persons who receive your health information may not be required by
Federal privacy laws (such as the HIPAA Privacy Rule) to protect it and may share your
information with others without your permission, if permitted by laws governing them.
In most cases, the health information that identifies you can be used or shared by the
research team only if you give your permission by signing this form. Your health
information may be shared with a public health authority that is authorized by law to
collect or receive such information for the purpose of preventing or controlling disease,
injury, or disability, and conducting public health surveillance, investigations or
interventions.
The time period when information can be used or shared ends when all activities related
to this study are completed.
Revocation of Research Authorization
You may withdraw the authorization you have given to use and share your protected
health information at any time. This means you can tell us to stop using and sharing your
protected health information. If you withdraw/revoke your authorization:
• We will stop collecting information about you.
• You may not withdraw information that we had before you told us to stop.
• We may already have used it or shared it.
• We may need it to complete the research.
• We may need it to search records that are available to the public.
1Staff may ask your permission to follow-up with you if there is a medical reason to do
so.
To withdraw your authorization, you will be requested to complete a written “Revocation
of Research Authorization” form located at the end of this document. You may also
obtain a copy from your study doctor, designated personnel or from the Human Subjects
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Protections Program Office website
(https://louisville.edu/research/humansubjects/templates/biomedical-forms)
Confidentiality
Total privacy cannot be guaranteed. Your privacy will be protected to the extent
permitted by law. If the results from this study are published, your name will not be made
public. While unlikely, the following may look at study records:
The University of Louisville Institutional Review Board, and Human Subjects
Protection Program Office, and/or the Office of Human Research Protections (OHRP).
This research is covered by a Certificate of Confidentiality from the National Institutes of
Health. The researchers with this Certificate may not disclose or use information or
documents that may identify you in any federal, state, or local civil, criminal,
administrative, legislative, or other action, suit, or proceeding, or be used as evidence.
Information or documents protected by this Certificate cannot be disclosed to anyone else
who is not connected with the research except, if there is a federal, state, or local law that
requires disclosure (such as to report child abuse, but not for federal, state, or local civil,
criminal, administrative, legislative, or other proceedings) if you have consented to the
disclosure, or if it is used for other scientific research, as allowed by federal regulations
protecting research subjects. If you report child abuse, or the intent to harm yourself or
others, the investigator is legally required to report such information which may result in
a breach of confidentiality and legal problems.
You should understand that a Certificate of Confidentiality does not prevent you from
voluntarily releasing information about yourself or your involvement in this research. If
you want your research information released to any other person not connected with the
research, you must provide consent to allow the researchers to release it.
Security
Your information will be kept private by placing it in a secure, locked cabinet and a
password protected computer accessible only by members of the study team.
Voluntary Participation
Taking part in this study is voluntary. You may choose not to take part at all. If you
decide to be in this study you may stop taking part at any time. If you decide not be in
this study or if you stop taking part at any time, you will not lose any benefits for which
you may qualify. It will not impact your relationship with the University of Louisville or
the Louisville Metro Department of Public health.
Contact Persons, Research Subject’s Rights, Questions Concerns, and Complaints
If you have any concerns or complaints about the study or the study staff, you have three
options.
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You may contact the principal investigators, Barbra Cave, at 502-852-2010 or
barbra.cave@louisville.edu or Vicki Hines-Martin at 502-852-8511 or
vphine01@louisville.edu
If you have any questions about your rights as a study subject, questions, concerns or
complaints, you may call the Human Subjects Protection Program Office (HSPPO) at
502-852-5188. You may discuss any questions about tour rights as a subject, in secret,
with a member of the Institutional Review Board (IRB) or HSPPO staff. The IRB is an
independent committee composed of members of the University community, staff of the
institutions, as well as lay members of the community not connected with these
institutions. The IRB has reviewed this study.
If you want to speak to a person outside the University, you may call 1-977-852-1167.
You will be given the chance to talk about any questions, concerns, or complaints in
secret. This is a 24-hour hotline answered by people who do not work at the University of
Louisville.
Acknowledgement and Signatures
This informed consent document is not a contract. This document tells you what will
happen during the study if you choose to take part. Your signature indicates that this
study has been explained to you, that your questions have been answered, and that you
agree to take part in the study. You are not giving up any legal rights to which you are
entitled by signing this informed consent document. You will be given a copy of this
consent form to keep for your records.

Subject Name (please print)

Signature of Subject

Date

Printed Name of Legal Representative

Signature of Legal Representative
(if applicable)

Date

Relationship of Legal Representative to Subject

Printed Name of Person Explaining
Consent Form

Signature of Person Explaining
Date
Consent Form (if other than Investigator)

Printed Name of Investigator

Signature of Investigator
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Date

List of Investigators:
Vicki Hines-Martin
Barbra Cave
Celeste Shawler
Rachel Vickers Smith
Laura Smart

Phone Numbers:
502-852-8511
502-852-2010
502-852-8391
502-852-8510
502-852-6991
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infected mothers and exposed infants to the primary outcomes: HCV cure for mothers
and confirmation of HCV infection or clearance in the child. Second year project includes
HCV screening expansion to the ULH emergency department with goals of linking all
HCV-infected adults to care. First year funding: $193,372. Second year funding:
$313,812.
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Study Tours on Infection Prevention and Control (IPC) Best Practices for Egyptian
Medical Professionals, Institute of International Education (IIE) US Agency for
International Development (USAID). PI: Ruth Carrico, PhD, DNP, APRN. Serving as
Co-Investigator and focusing on hepatitis C virus infection prevention, control, and
treatment; October-December 2018. Grant award: $272,511

PEER-REVIEWED JOURNAL PUBLICATIONS
Crittenden, N. E., Buchanan, L. A., Pinkston, C. M., Cave, B., Barve, A....
& Kuns‐Adkins, C.B. (2016). Simeprevir and sofosbuvir with or without ribavirin to treat
recurrent genotype 1 hepatitis C virus infection after orthotopic liver
transplantation. Liver Transplantation. PMID 26915588
Reddy, K., Patrick, C., Liaquat, H., Rodriquez, E., Stocker, A., Cave, B., …Abell, T.
(2018). Differences in referral access to gastrointestinal subspecialty patients: Barriers
and opportunities. Health Equity 2(1). doi: 10.1089/heq.2018.0001

PUBLISHED ABSTRACTS
Cave, B.A., Higdon, K., Pasquenza, N., & Espinosa, C.M. (2019, October). Factors
associated with linkage-to-care after delivery. To be published in Hepatology (70)4.
Hoboken, NJ: Wiley-Blackwell.
Crittenden, N., Davis, E. G., Marsano, L. S., McClain, C. J., Barve, A., Goshko, B. A., &
Cave, M. C. (2014, January). Single center experience with simeprevir/sofosbuvir
combination therapy for recurrent hepatitis C virus infection in liver transplant recipients.
In Hepatology (Vol. 60, p. 700A). Hoboken, NJ: Wiley-Blackwell.

CONFERENCE PRESENTATIONS
Cave, B.A. “HCV: Current state and elimination strategies” presented at the 2019
Gastroenterology/Hepatology Advance Practice Providers Conference in Las Vegas, NV
on September 6, 2019. (Podium)
Cave, B.A. “Quick assessment and management of viral hepatitis” presented at the 2019
University of Louisville Hospital Advanced Practice Provider Conference in Louisville,
KY on August 23, 2019. (Podium)
Cave, B.A, “KHAMP: The role of expert mentoring in hepatitis C elimination” Presented
at the 6th Annual Kentucky Viral Hepatitis Conference on July 31, 2019 in Lexington,
KY. (Podium)
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Cave, B.A, “UofL FOCUS: HCV care navigation for mothers and infants” Presented at
the 6th Annual Kentucky Viral Hepatitis Conference on July 31, 2019 in Lexington, KY.
(Podium)
Cave, B.A. “Trifecta! Kentucky leads in viral hepatitis A, B, & C” Presented at the 2019
Kentucky Coalition of Nurse Practitioners and Nurse Midwives Conference on April 24,
2019 in Covington, KY. (Podium)
Cave, B.A., Sanders, K.J., Wilburn, A., Barve, A.J., Hill, B.L. … & Espinosa, C. (2019,
February). “Scaling up HCV care in Appalachia: The Kentucky Hepatitis Academic
Mentorship Program (KHAMP)” presented at the AASLD/IDSA Special HCV
Conference in Miami, FL on February 1, 2019. (Poster)
Cave, B.A., Pasquenza, N., Higdon, K., Davis, D.W., & Espinosa, C. (2018, October).
“Care navigation for moms and babies after reactive universal hepatitis C virus
screening.” Presented at Research! Louisville on October 10, 2018 in Louisville, KY.
Abstract #NS 6. Winner of the 2018 UofL School of Nursing Graduate Poster Award.
Cave, B.A. & Hanson, C. “Recent Hepatitis C Treatment Advances” presented at the
inaugural Gastroenterology/Hepatology Advance Practice Providers Conference in Las
Vegas, NV on September 7, 2018. (Podium)
Cave, B.A. “The Next Era in Hepatitis C Treatment: Bringing Cure to Primary Care”
presented at the Center for Health, Education, and Research in Morehead, KY on August
7, 2018. (Podium)
Cave, B.A., & Revert, D.H. (2018). “Best Practices in HCV Diagnosis and Linkage to
Care” presented at the 5th Annual Kentucky Viral Hepatitis Conference in Lexington, KY
on July 31, 2018. (Podium)
Cave, B.A. “NASH: From Steatosis to Cirrhosis” presented at the 30 th Annual Kentucky
Coalition of Nurse Practitioners and Nurse Midwives Conference on April 20, 2018
(Podium)
Cave, B.A., Beeber, H., Sanders, K.J., O’Donnell, J. & Smart, L. (2017, September).
“Large-scale hepatitis C screening and the changing epidemiology of hepatitis C in
Kentucky.” Research! Louisville 2017 in Louisville, KY. Abstract #NS 3. Winner of the
2017 UofL School of Nursing Graduate Poster Award.
Cave, B.A. “Justifying the Cure: Kentucky’s Drug Users Should Have Access to HCV
Treatment” presented at the 4th Annual Kentucky Viral Hepatitis Conference in
Lexington, KY on July 27, 2017 (Podium)
Cave, B.A. “Advocacy and Access: When Your Patient Needs an Oil Change” presented
at the 4th Annual Kentucky Viral Hepatitis Conference in Lexington, KY on July 27,
2017 (Podium)
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Cave, B.A. “The New Age of Hepatitis C: Diagnosis and Treatment” (Abstract#
9197387) presented at the 29th Annual Kentucky Coalition of Nurse Practitioners and
Nurse Midwives Conference on April 20, 2017 in Covington, KY (Podium)
Cave, B.A. “Hepatitis C Treatment Access and Advocacy” (revised from 2015) presented
at the 3rd Annual Kentucky Viral Hepatitis Conference in Lexington, KY on July 26,
2016. http://chfs.ky.gov/dph/diseases/Hepatitis+C.htm (Podium)
Cave, B.A. “The Viral Hepatitis Epidemic in Kentucky” presented at the Kentucky
Public Health Association Annual Conference, Owensboro, KY on April 12, 2016.
(Podium)
Cave, B.A. “Hepatitis C: Diagnosis, Treatment, and Linkage to Care” presented at the
Kentucky Academy of Physician Assistants annual CME Symposium event, Lexington,
KY, on November 5, 2015. http://kentuckypa.org/events-cme/2015-kapa-cmesymposium (Podium)
Cave, B.A., Lunn, S. M., Smart, L.E., Sanders, K.J., Cave, M.C., Carrico, R.M. (2015,
October).”Viral Hepatitis Screening at the 2015 Kentucky State Fair Determined a Rate
of Hepatitis C Infection Approximately Three Times the National Average.” Research!
Louisville 2015 in Louisville, KY. Abstract #RS-82 (Poster)
Goshko, B.A. “Hepatitis C Treatment Access and Advocacy” presented at the 2 nd Annual
Kentucky Viral Hepatitis Conference, Lexington, KY on July 28, 2015.
Goshko, B.A. “Viral Hepatitis: Alphabet Soup” presented at the Kentucky Coalition of
Nurse Practitioners and Nurse Midwives 27th Annual Conference, Covington, KY, April
25, 2015. (Podium)

CONSULTING
Dova Pharmaceuticals, Avatrombopag Advisory Committee, January 2018-March
2019.

ADVISORY BOARD MODERATNG
Abbvie: Assessing the needs of new HCV treaters, Chicago, IL; December 2018.

SPEAKER BUREAUS
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Gilead, Sovaldi (sofosbuvir), October 2013-Present, Harvoni (sofosbuvir/ledipasvir),
October 2014-Present, Epclusa (sofosbuvir/velpatasvir) June 2016-Present, Vosevi
(sofosbuvir/velpatasvir/voxilaprevir) July 2017-Present.
Abbvie, Humira (adalimumab), January 2014-December 2018; Viekira Pak (ombitasvir,
ritonavir, dasabuvir, and paritaprevir), December 2014-July 2017; Technivie (ombitasvir,
paritaprevir, and ritonavir), July 2015-July 2017, Mavyret (glecaprevir/pribentasvir) July
2017-Present.
Merck, Zepatier (elbasvir/grazoprevir), February 2016-September 2017.
Bristol Myers Squibb, Daklinza (daclatasvir), June 2015-August 2016.
Salix, Xifaxan (rifaxamin) and Relistor (methylnaltrexone), November 2012-January
2016, and Xifaxan (rifaximin) January-December 2018.
Entera Health, Enteragam (serum-derived bovine immunoglobulin/protein isolate),
March 2015-March 2016.
Janssen, National Speaker on Simponi (golimumab), June 2014-March 2016: Assisted
with deck development and served as faculty presenter for an updated Simponi deck in
February 2015. Olysio (simeprevir) December 2013-October 2015. Remicade
(infliximab) February 2015-March 2016.
Vertex, Incivek (telaprevir), January 2013-November 2013.

CLINICAL TRIALS
Co-Primary Investigator 386540: Analysis of Hepatitis C Data from the Screening
Performed at the Kentucky State Fair. 15.0748
Sub-Investigator 0151003(ANDANTE): A Double-Blind, Randomized, PlaceboControlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of PD-04236921 in
Subjects with Crohn's Disease who are Anti-TNF Inadequate Responders 11.0228.
B0151005 (ADANTE II): Extension study. 11.0467
Sub-Investigator TU100P2T2 - A Multi-Center, Randomized, Double-Blinded, PlaceboControlled Study of Daikenchuto (TU-100) in Subject with Moderate Crohn's Disease.
11.0568 (Completed)
Sub-Investigator CNDO 201-003: A Phase II Study to Evaluate the Efficacy and Safety
of 12 Weeks of Treatment with Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as
compared to Placebo, Followed by a 12 Week Open-Label Treatment Period in Patients
with Moderately to Severely Active Crohn's Disease 12.0364 (Completed)
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Sub-Investigator CNT01275CRD3003 (IMUNITI): A Phase 3, Randomized, Doubleblind, Placebo Controlled, Parallel-group, Multicenter Study to Evaluate the Safety and
Efficacy of Ustekinumab Maintenance Therapy in Subjects with Moderately to Severely
Active Crohn's Disease 11.0476 (Completed)
Sub-Investigator Protocol CNTO1275CRD3002 (UNITI-2) / A Phase 3, Randomized,
Double—blind, Placebo—controlled, Parallel—group, Multicenter Study to Evaluate the
Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to
Severely Active Crohn´s Disease 13.0362 (Completed)
Sub-Investigator IM129-005: A Phase IIb Randomized, Placebo-Controlled Study to
Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with
BMS-936557 in Subjects with Active Ulcerative Colitis (UC) 11.0226 (Completed)
Sub-Investigator MK5172-038: A Phase II Randomized, Dose Ranging, Clinical Trial to
Evaluate the Safety, Tolerability and Efficacy of Different Doses of MK5172 when
Administered Concomitantly with Peginterferon alpa-2b and Ribavirin in Treatment
Naive Subjects with Chronic Hepatitis C Virus Infection 12.0564 (Completed)
Sub-Investigator MK5172-068: A Phase III Randomized Clinical Trial to Study the
Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Subjects who
have Failed Prior Treatment with PEGylated Interferon and Ribavirin (P/R) with
Chronic HCV GT1, GT4, GT5, and GT6 Infection 12.0424
Sub-Investigator Protocol MK5172-017-00: A Long-Term Follow-up Study to Evaluate
the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects with
Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior
Clinical Trial 12.0512
Sub-Investigator MK5172-PN-003: A Randomized, Active-Controlled, Dose-Ranging
Estimation Study to Evaluate the Safety, Tolerability and Efficacy of Different Regimens
of MD-5172 when Administered Concomitantly with Peginterferon alfa-2b and Ribavirin
in Treatment-Naive Patients with Chronic Genotype 1 Hepatitis C Virus Infection
11.0301 (Completed)
Sub-Investigator Novel Therapies for Alcoholic Hepatitis 12.0427
Sub-Investigator PO7755(MK-3034-040-01): A Phase 3, Safety and Efficacy Study of
Boceprevir/Peginterferon Alfa-2a/ribavirin in Chronic HCV Genotype 1 IL28B CC
Subjects 12.0383 (Completed)
Sub-Investigator Protocol 27018966IBS3001: A Randomized, Double-blind, Placebocontrolled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ27018966 in the Treatment of Patients with Diarrhea-Predominant Irritable Bowel
Syndrome 12.0226 (Completed)
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Sub-Investigator Protocol ACT12688: A Randomized, Double-blind, Placebocontrolled, Multicenter Study Evaluating Efficacy and Safety of SAR339658 in Patients
with Active Moderate to Severe Ulcerative Colitis (UC) 13.0339 (Completed)
Sub-Investigator Protocol IDN-6556-02 / A Placebo-Controlled, Multicenter, DoubleBlind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN-6556 in
Subjects with Acute-on-Chronic Liver Failure (Conatus) 13.0976 (Completed)
Sub-Investigator Protocol C13008: A Phase 3, Open-label Study to Determine the
Long-Term Safety and Efficacy of Vedolizumab (MLN0002) in Patients with Ulcerative
Colitis and Crohn’s Disease 08.0515
Sub-Investigator Protocol LUM001-201: A Phase 2, Randomized, Double-Blind,
Placebo-Controlled Study to Evaluate LUM001, an Apical Sodium-Dependent Bile Acid
Transporter Inhibitor (ASBTi) in Combination with Ursodeoxycholic Acid (UDCA) in
Patients with Primary Biliary Cirrhosis 13.0288 (Completed)
Sub-Investigator Merit-UC: Randomized, Double Blind, Prospective Trial Investigating
the Efficacy of Methotrexate in Induction and Maintenance of Steroid Free Remission in
Ulcerative Colitis (Methotrexate Response in Treatment of UC-Merit-UC) 12.0246
Sub-Investigator Protocol MK-3415A-002 (MODIFY II): A Phase III, Randomized,
Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of a
Single Infusion of MK-6072 (Human Monoclonal Antibody to C. difficile toxin B), and
MK-3415A (Human Monoclonal Antibodies to C. difficile toxin A and B) in Patients
Receiving Antibiotic Therapy for C. difficile Infection 12.0028 (Completed)
Sub-Investigator CLARITY-1: A Balanced, Randomized, Placebo-Controlled, DoubleBlind Study of the Efficacy and Safety of AUT00063 Versus Placebo in Age-Related
Hearing Loss 14.1295 (Completed)
Sub-Investigator Receptos Ulcerative Colitis Open Label Extension: A Phase 3,
Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to
Severe Ulcerative Colitis 15.0688
Independent Assessor CONCERNT-HF: A Phase II, Randomized, Placebo-Controlled
Study of the Safety, Feasibility, and Efficacy of Autologous Mesenchymal Stem Cells and
c-kit+ Cardiac Stem Cells, Alone or in combination, Administered Transendocardially in
Subjects with Ischemic Heart Failure 15.0733
Sub-Investigator Hep C with Simeprevir, Sofosbuvir, and Ribavirin: A Retrospective
Review of the Treatment of Hepatitis C Virus Genotype 1 Patients with Simeprevir,
Sofosbuvir, With and Without Ribavirin at University of Louisville/Jewish Hospital
14.1239
Sub-Investigator Protocol IDN-6556-07 (Conatus-POLT): A Multicenter, Double140

Blind, Randomized Trial of IDN-6556 in Subjects Who had Hepatitis C Virus (HCV)
Reinfection and Liver Fibrosis or Cirrhosis Following Orthotopic Liver Transplantation
for Chronic HCV Infection and Who Subsequently Achieved a Sustained Virologic
Response Following anti-HCV Therapy 15.0242
Sub-Investigator GED-0301-CD-001 (Celgene Crohn’s) - A Randomized, DoubleBlind, Multicenter Study To Explore The Effect Of Ged-0301 On Endoscopic And
Clinical Outcomes In Subjects With Active Crohn’s Disease 15.0186
Sub-Investigator Protocol M13-740 / A Multicenter, Randomized, Double-Blind,
Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic
Remission in Subjects with Moderately to Severely Active Crohn's Disease who have
Inadequately Responded to or are Intolerant to Immunomodulators or Anti-TNF Therapy
15.0141
Sub-Investigator Novartis PBC: CLJN452X2201 A multi-part, randomized, doubleblind, placebo-controlled study to assess the safety, tolerability, and efficacy of LJN452
in Patients with Primary Biliary Cirrhosis 15.0809
Sub-Investigator Xpert HCV VL Assay: Clinical Evaluation of the Xpert HCV VL Assay
15.0305 (Completed)
Sub-Investigator Protocol GA29144 Open-Label Crohn’s Disease: An Open-Label
Extension and Safety Monitoring Study of Patients with Moderately to Severely Active
Crohn’s Disease Previously Enrolled in the Etrolizumab Phase III 15.0375
Sub-Investigator Gilead 0102 Primary Sclerosing Cholangitis: GS-US-321-0102/A
Phase 2b, Dose-ranging, Randomized, Double-Blind, Placebo-Controlled Trial
Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl
Oxidase-Like 2 (LOXL2), in Subjects with Primary Sclerosing Cholangitis (PSC) 13.0517
Sub-Investigator Gilead 0105 Advanced Liver Fibrosis: GS-US-321-0105/A Phase 2b,
Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the
Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2
(LOXL2), in Subjects with Advanced Liver Fibrosis but not Cirrhosis Secondary to NonAlcoholic Steatohepatitis (NASH) 13.0518
Sub-Investigator Gilead 0106 Compensated Cirrhosis: GS-US-321-0106/A Phase 2b,
Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the
Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2
(LOXL2), in Subjects with Compensated Cirrhosis Secondary to Non-Alcoholic
Steatohepatitis (NASH) 13.0539
Independent Assessor Heartmate III (MOMENTUM 3): Multi-Center Study of MagLev
Technology in Patients Undergoing MCS Therapy with Heartmate 3 15.0347
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Sub-Investigator Protocol CNTO1275UCO3001 (UNIFI): A Phase 3, Randomized,
Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the
Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects with
Moderately to Severely Active Ulcerative Colitis 15.0638
Independent Assessor SENECA: A Phase I, First-in-Human, Multicenter, Randomized,
Double-Blinded, Placebo-Controlled Study of the Safety and Efficacy of Allogenic
Mesenchymal Stem Cells in Cancer Survivors with Anthracycline-Induced
Cardiomyopathy 15.0928
Sub-Investigator PERSEUS Tobira: A Phase 2 Proof of Concept Study Investigating
the Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects with Primary
Sclerosing Cholangitis (PSC) 16.0015
Sub-Investigator Roche GA28951: An Open-Label Extension and Safety Monitoring
Study of Moderate to Severe Ulcerative Colitis Patients Previously Enrolled in
Etrolizumab Phase III Studies 14.0533
Sub-Investigator Protocol 652-2-203 (Tobira NASH): CENTAUR-Efficacy and Safety
Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in
Adult Subjects with Liver Fibrosis 14.1274
Sub-Investigator Protocol 747-302 (Intercept PBC): A Phase 3b, Double-Blind,
Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obetacholic
Acid on Clinical Outcomes in Subjects with Primary Biliary Cirrhosis 14.1228
Sub-Investigator Protocol 747-303 (Intercept NASH): A Phase 3, Double-Blind,
Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety
and Efficacy of Obetacholic Acid in Subjects with Nonalcoholic Steatohepatitis (NASH)
15.0879
Sub-Investigator Protocol APD334-003 Arena Ulcerative Colitis: A Phase 2,
Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to
Investigate the Safety and Efficacy of APD334 in Patients with Moderately to Severely
Active Ulcerative Colitis 15.0696 (Completed)
Sub-Investigator Protocol CC-10004-UC-001 Celgene Ulcerative Colitis: A Phase 2,
randomized, placebo-controlled, multicenter study to investigate the efficacy and safety
of apremilast (CC-10004) for treatment of subjects with active ulcerative colitis 14.1249
Sub-Investigator Protocol GA28948: Phase III, Randomized, Double-Blind, DoubleDummy, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Induction of
Remission) and Safety of Etrolizumab Compared with Adalimumab and Placebo in
Patients with Moderate to Severe Ulcerative Colitis Who Are Naïve to TNF Inhibitors
14.0881

142

Sub-Investigator Protocol GA28950: Phase III, Double-Blind, Placebo-Controlled,
Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and
Maintenance in Patients with Moderate to Severe Ulcerative Colitis Who Are Refractor
or Intolerant of TNF Inhibitors 14.0220
Sub-Investigator Protocol GA29144: A Phase III, Randomized, Double-Blind, PlaceboControlled, Multicenter Study to Evaluate the Efficacy and Safety of Etrolizumab as an
Induction and Maintenance Treatment for Patients with Moderately to Severely Active
Crohn’s Disease 15.0252
Sub-Investigator Protocol GS-US-326-1100 (Gilead UC): A Combined Phase 2/3,
Double-Blind, Randomized, Placebo-Controlled, Induction and Maintenance Study
Evaluating the Safety and Efficacy of GS-5745 in Subjects with Moderately to Severely
Active Ulcerative Colitis 15.0904
Sub-Investigator and Coordinator Protocol IDN-6556-10 (Conatus Cirrhosis): A
Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability
and Efficacy of IDN-6556 in Subjects with Liver Cirrhosis 14.0613 (Completed)
Sub-Investigator and Coordinator Protocol IDN-6556-02 (Conatus): A PlaceboControlled, Multicenter, Double-Blind, Randomized, Pharmacokinetic and
Pharmacodynamic Trial of IDN-6556 in Subjects with Acute-on-Chronic Liver Failure
13.0976 (Completed)
Sub-Investigator RPC01-301 (Receptos 3101 UC): A Phase 3, Multicenter,
Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and
Maintenance Therapy for Moderate to Severe Ulcerative Colitis 15.0586
Sub-Investigator Protocol BAY 86-9766: A prospective, single-arm, multicenter,
uncontrolled, open-label Phase II trial of refametinib (BAY 86-9766) in patients with
RAS mutant Hepatocellular Carcinoma (HCC) 13.0432 (Completed)
Sub-Investigator PF-05285401: A Phase 2 Randomized, Double-Blind, PlaceboControlled, Parallel Group, Multi-center Study to Investigate the Safety and Efficacy of
MultiStem (PF-05285401) in Subjects with Moderate to Severe Ulcerative Colitis
10.0594 (Completed)
Sub-Investigator Protocol HVB-02-13 (HBV Assay): Multicenter, Prospective
Evaluation of the Beckman Coulter DxN HBV Viral Load Assay as an Aid in the
Management of HBV-infected Individuals Undergoing Antiviral Therapy 14.0236
(Completed)
Sub-Investigator Protocol LTS12593 (Sanofi Extension): A multicenter single-arm
open-label extension study evaluating the long-term safety and tolerability of SAR339658
in patients with Ulcerative Colitis (UC) 13.0875 (Completed)
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Sub-Investigator Protocol D5170C00002 (MedImmune Crohn’s): Phase 2b Doubleblind, Multi-dose, Placebo-controlled Study to Evaluate the Efficacy and Safety of
MEDI2070 in Subjects with Moderate to Severe Crohn’s Disease Who Have Failed or
Are Intolerant to Anti-tumor Necrosis Factor-alpha Therapy 16.0093
Sub-Investigator Protocol IDN-6556-12 (Conatus NASH): A Multicenter, Randomized,
Double-blind, Placebo-Controlled Trial of Emricasan (IDN-6556), an Oral Caspase
Inhibitor, in Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis 16.0115
Sub-Investigator PIONEER-CD: A Randomized, Double-Blind, Placebo-Controlled
Trial to Evaluate the Effectiveness of a Nutritional Intervention in Improving the
Intestinal Mucosal Health Status in Subjects with Crohn’s Disease (CD) Receiving
Induction Anti-TNF Therapy 16.0616
Sub-Investigator GFT505-315-1 (GENFIT NASH): A Multicenter, Randomized,
Double-blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of
Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis 16.0637
Sub-Investigator Protocol SHP626-201 (Shire NASH): A Phase 2 Double-Blind,
Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability
and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter
Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis 16.0666
Sub-Investigator Protocol GS-US-366-1992: A Phase 3b Randomized, Open-label,
Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of
Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co infected Subjects who
Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or
Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) prior to LDV/SOF HCV
Treatment, the HIV/HCV Co-STARs study (Co-infection treatment with Single Tablet
Antiviral Regimens) 16.0799

SERVICE
Bellarmine University Alumni Board of Directors¸ Louisville, Kentucky
Executive Committee, Ex-Officio 2016-2017, Alumni Association President 2015-2016,
Vice-President 2014-2015.Young Alumni Committee, June 2009-2014. Committee Chair
2012-2014.
Amateur Athletic Union, TaeKwonDo Certified Official, Class C, 2014-2015; Class D
2013. AAU member 2001-Present.
River TaeKwonDo, Black Belt and Instructor, 5th Dan, 1999-Present.
National Kidney Foundation Gift of Life Gala Board, Louisville Chapter, Logistics
Committee, October 2011-March 2014.
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LICENSURE/
Maiden name: Barbra A. Peper
CREDENTIALING Former name: Barbra A. Goshko (2005-2015)
DETAILS
Legal name: Barbra A. Cave
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